var title_f17_46_18144="Posterior labial fusion";
var content_f17_46_18144=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F51835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F51835&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Posterior labial fusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 390px; height: 262px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Posterior labial fusion in the 46,XX patient with ovotesticular disorder of sex development (previously known as true hermaphroditism) who also has clitormegaly and gonads palpaple in the labioscrotal folds.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Christopher P Houk, MD and Lynne L Levitsky, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18144=[""].join("\n");
var outline_f17_46_18144=null;
var title_f17_46_18145="Palpation lateral epicondyle";
var content_f17_46_18145=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F64356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F64356&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Palpation of the lateral epicondyle",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The lateral epicondyle is palpated for tenderness and swelling with the elbow flexed at 90 degrees. Local tenderness is&nbsp;a hallmark feature of lateral epicondylitis (tennis elbow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18145=[""].join("\n");
var outline_f17_46_18145=null;
var title_f17_46_18146="Patient information: Quitting smoking (The Basics)";
var content_f17_46_18146=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?42/0/43011\">",
"         Patient information: Cough in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?0/37/595\">",
"         Patient information: Secondhand smoke: Risks to children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/13/19670\">",
"         Patient information: Quitting smoking (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Quitting smoking (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/quitting-smoking-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H470671210\">",
"      <span class=\"h1\">",
"       What are the benefits of quitting smoking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Quitting smoking can lower your chances of getting or dying from heart disease, lung disease, or cancer. It can also lower your chances of getting osteoporosis, a condition that makes your bones weak. Plus, quitting smoking can help your skin look younger and reduce the chances that you will have problems with sex.",
"     </p>",
"     <p>",
"      Quitting smoking will improve your health no matter how old you are, and no matter how long or how much you have smoked.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671217\">",
"      <span class=\"h1\">",
"       What should I do if I want to quit smoking?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The letters in the word &ldquo;START&rdquo; can help you remember the steps to take:",
"     </p>",
"     <p>",
"      <strong>",
"       S",
"      </strong>",
"      = Set a quit date.",
"     </p>",
"     <p>",
"      <strong>",
"       T",
"      </strong>",
"      = Tell family, friends, and the people around you that you plan to quit.",
"     </p>",
"     <p>",
"      <strong>",
"       A",
"      </strong>",
"      = Anticipate or plan ahead for the tough times you'll face while quitting.",
"     </p>",
"     <p>",
"      <strong>",
"       R",
"      </strong>",
"      = Remove cigarettes and other tobacco products from your home, car, and work.",
"     </p>",
"     <p>",
"      <strong>",
"       T",
"      </strong>",
"      = Talk to your doctor about getting help to quit.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671224\">",
"      <span class=\"h1\">",
"       How can my doctor or nurse help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor or nurse can give you advice on the best way to quit. He or she can also put you in touch with counselors or other people you can call for support. Plus, your doctor or nurse can give you medicines to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Reduce your craving for cigarettes",
"       </li>",
"       <li>",
"        Reduce the unpleasant symptoms that happen when you stop smoking (called &ldquo;withdrawal symptoms&rdquo;).",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      You can also get help from a free phone line (1-800-QUIT-NOW) or go online to",
"      <a class=\"external\" href=\"file://www.smokefree.gov/\">",
"       www.smokefree.gov",
"      </a>",
"      .",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671231\">",
"      <span class=\"h1\">",
"       What are the symptoms of withdrawal?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Trouble sleeping",
"       </li>",
"       <li>",
"        Being irritable, anxious or restless",
"       </li>",
"       <li>",
"        Getting frustrated or angry",
"       </li>",
"       <li>",
"        Having trouble thinking clearly",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Some people who stop smoking become temporarily depressed. Some of them need treatment for depression, such as counseling or antidepressant medicines. If you get depressed when you quit smoking, tell your doctor or nurse about it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671238\">",
"      <span class=\"h1\">",
"       How do medicines help?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Different medicines work in different ways:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        <strong>",
"         Nicotine replacement therapy",
"        </strong>",
"        eases withdrawal and reduces your body&rsquo;s craving for nicotine, the main drug found in cigarettes. Non-prescription forms of nicotine replacement include skin patches, lozenges, and gum. Prescription forms include nasal sprays and &ldquo;puffers&rdquo; or inhalers.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=see_link\">",
"         Bupropion",
"        </a>",
"        is a prescription medicine that reduces your desire to smoke. This medicine is sold under the brand names Zyban&reg; and Wellbutrin&reg;. It is also available in a generic version, which is cheaper than brand-name medicines.",
"       </li>",
"       <li>",
"        <a class=\"drug drug_patient\" href=\"UTD.htm?9/9/9365?source=see_link\">",
"         Varenicline",
"        </a>",
"        (brand name: Chantix&reg;) is a prescription medicine that reduces withdrawal symptoms and cigarette cravings. If you think you&rsquo;d like to take varenicline and you have a history of depression, anxiety, or heart disease, discuss this with your doctor or nurse before taking the medicine.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you take",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=see_link\">",
"       bupropion",
"      </a>",
"      or",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?9/9/9365?source=see_link\">",
"       varenicline",
"      </a>",
"      and you have any of the following symptoms, stop taking the medicine and call your doctor or nurse:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Become very nervous",
"       </li>",
"       <li>",
"        Become depressed",
"       </li>",
"       <li>",
"        Start to do strange things",
"       </li>",
"       <li>",
"        Think about killing yourself",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671245\">",
"      <span class=\"h1\">",
"       How does counseling work?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Counseling can happen during formal office visits or just over the phone. A counselor can help you:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Figure out what triggers your smoking and what to do instead",
"       </li>",
"       <li>",
"        Overcome cravings",
"       </li>",
"       <li>",
"        Figure out what went wrong when you tried to quit before",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671252\">",
"      <span class=\"h1\">",
"       What works best?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Studies show that people have the best luck at quitting if they take medicines to help them quit",
"      <strong>",
"       and",
"      </strong>",
"      work with a counselor. It might also be helpful to combine nicotine replacement with one of the prescription medicines that help people quit.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671259\">",
"      <span class=\"h1\">",
"       Will I gain weight if I quit?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, you might gain a few pounds. But quitting smoking will have a much more positive effect on your health than weighing a few pounds more. Plus, you can help prevent some weight gain by being more active and eating less. Taking the medicine",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?17/7/17526?source=see_link\">",
"       bupropion",
"      </a>",
"      might help control weight gain.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671266\">",
"      <span class=\"h1\">",
"       What else can I do to improve my chances of quitting?",
"      </span>",
"      &nbsp;&mdash;&nbsp;You can:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Start exercising",
"       </li>",
"       <li>",
"        Stay away from smokers and places that you associate with smoking. If people close to you smoke, ask them to quit with you.",
"       </li>",
"       <li>",
"        Keep gum, hard candy, or something to put in your mouth handy. If you get a craving for a cigarette, try one of these instead.",
"       </li>",
"       <li>",
"        Don&rsquo;t give up, even if you start smoking again. It takes most people a few tries before they succeed.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671273\">",
"      <span class=\"h1\">",
"       What if I am pregnant and I smoke?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you are pregnant, it&rsquo;s really important for the health of your baby that you quit. Ask your doctor what options you have, and what is safest for your baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H470671280\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=see_link\">",
"       Patient information: Cough in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=see_link\">",
"       Patient information: Secondhand smoke: Risks to children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=see_link\">",
"       Patient information: Quitting smoking (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?17/46/18146?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15429 Version 6.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-197.136.42.3-BD8FD8CCCA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18146=[""].join("\n");
var outline_f17_46_18146=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671210\">",
"      What are the benefits of quitting smoking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671217\">",
"      What should I do if I want to quit smoking?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671224\">",
"      How can my doctor or nurse help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671231\">",
"      What are the symptoms of withdrawal?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671238\">",
"      How do medicines help?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671245\">",
"      How does counseling work?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671252\">",
"      What works best?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671259\">",
"      Will I gain weight if I quit?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671266\">",
"      What else can I do to improve my chances of quitting?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671273\">",
"      What if I am pregnant and I smoke?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H470671280\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?42/0/43011?source=related_link\">",
"      Patient information: Cough in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?19/13/19670?source=related_link\">",
"      Patient information: Quitting smoking (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?0/37/595?source=related_link\">",
"      Patient information: Secondhand smoke: Risks to children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18147="Fluoxymesterone: Pediatric drug information";
var content_f17_46_18147=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Fluoxymesterone: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"    see \"Fluoxymesterone: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?17/61/18388?source=see_link\">",
"    see \"Fluoxymesterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F172812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Androxy&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1058754\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Androgen",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1058749\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=see_link\">",
"      see \"Fluoxymesterone: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Male:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hypogonadism: 5-20 mg/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delayed puberty: 2.5-20 mg/day for 4-6 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Female:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Inoperable breast carcinoma: 10-40 mg/day in divided doses for 1-3 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Breast engorgement: 2.5 mg after delivery, 5-10 mg/day in divided doses for 4-5 days",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F172797\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Androxy&trade;: 10 mg [scored]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F172780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F172840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-III",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1058757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Replacement of endogenous testicular hormone; in females used as palliative treatment of breast cancer, postpartum breast engorgement",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F172847\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Halotestin [Great Britain] may be confused with Haldol brand name for haloperidol [U.S. and multiple international markets]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F172844\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Male:",
"     </b>",
"     Gynecomastia, oligospermia (at higher doses), priapism, prostatic carcinoma, prostatic hypertrophy, testicular atrophy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Female:",
"     </b>",
"     Menstrual irregularities (including amenorrhea), virilism (including deepening of the voice, clitoris hypertrophy)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, headache",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Acne, hirsutism, &ldquo;male pattern&rdquo; baldness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Electrolyte abnormalities (sodium, chloride, calcium, potassium, and inorganic phosphate retention), hypercholesterolemia, libido changes (increased or decreased), water retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: GI irritation, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Prostatic hyperplasia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Clotting factor suppression, polycythemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice, hepatic coma (rare), hepatic dysfunction, hepatocellular neoplasms (rare), liver function tests abnormal, peliosis hepatitis (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Paresthesia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Hypersensitivity, nonimmunologic anaphylaxis (formerly known as anaphylactoid reaction)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1058760\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to fluoxymesterone or any component; serious cardiac disease, liver or kidney disease",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1058748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     May accelerate bone maturation without producing compensatory gain in linear growth; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1058747\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     . Some tablets (brand name) contain tartrazine which may cause allergic reactions in susceptible individuals.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299354\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F172789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F172792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     X (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F13386438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use is contraindicated in women who are or may become pregnant. May cause androgenic effects to the female fetus; clitoral hypertrophy, labial fusion, urogenital sinus defect, vaginal atresia, and ambiguous genitalia have been reported.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1058753\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Periodic radiographic exams of hand and wrist (when used in children); hemoglobin, hematocrit (if receiving high dosages or long-term therapy)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1058746\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Synthetic androgenic anabolic steroid hormone responsible for the normal growth and development of male sex organs and maintenance of secondary sex characteristics; synthetic testosterone derivative with significant androgen activity; stimulates RNA polymerase activity resulting in an increase in protein production; increases bone development",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1058759\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Rapid",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 98%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 10-100 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Enterohepatic circulation and urinary excretion (90%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Halogenated derivative of testosterone with up to 5 times the activity of methyltestosterone",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13316 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0502-210.101.131.231-1C6C0C3C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18147=[""].join("\n");
var outline_f17_46_18147=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172812\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058754\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058749\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172797\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172840\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058757\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172847\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172844\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058760\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058748\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058747\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299354\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F172792\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13386438\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058753\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058746\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1058759\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13316\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13316|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?40/34/41508?source=related_link\">",
"      Fluoxymesterone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?17/61/18388?source=related_link\">",
"      Fluoxymesterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18148="Diverticulum PI";
var content_f17_46_18148=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F82042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F82042&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 608px\">",
"   <div class=\"ttl\">",
"    Diverticulum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 588px; height: 560px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure depicts the various parts of the colon (also known as the large intestine), the rectum, and the anus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Insert reproduced with permission from: Anatomical Chart Company. Copyright &copy; 2008 Wolters Kluwer Health.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18148=[""].join("\n");
var outline_f17_46_18148=null;
var title_f17_46_18149="Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis";
var content_f17_46_18149=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Steven Flamm, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Andre A Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Raoul Poupon, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Paul Angulo, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18149/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/46/18149/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 7, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercholesterolemia is a common feature of primary biliary cirrhosis (PBC) and other forms of cholestatic liver disease. The mechanism of hyperlipidemia in cholestatic disorders is different from that in other conditions as unusual lipoprotein particles, such as lipoprotein X, may accumulate and levels of HDL cholesterol are typically elevated. An important question is whether these patients are at risk for the complications of hypercholesterolemia? The available data suggest that, despite hypercholesterolemia, patients with PBC are",
"    <strong>",
"     not",
"    </strong>",
"    at increased risk of atherosclerosis. However, a small minority of patients with PBC may have independent abnormalities of lipid metabolism. If there is any question, PBC patients should have fasting lipoprotein profiles performed to assess the risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVALENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial studies suggested that the total plasma cholesterol was elevated in 50 percent of patients with PBC, although this prevalence was based upon normal ranges which included values from 218",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    to 300",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.7 to 7.9",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/1\">",
"     1",
"    </a>",
"    ]. The mean plasma cholesterol concentrations in this study were 285",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (7.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in asymptomatic patients and 377",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (9.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in symptomatic patients in this study. Later studies confirmed these findings; 89 percent and 96 percent of patients had total plasma cholesterol values above 200",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (5.2",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. However, the range of values was extremely wide, from 120",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    to 1775",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (46.1",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in one report of 284 patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/4\">",
"     4",
"    </a>",
"    ]. There was no correlation between total cholesterol and total bilirubin levels.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CHOLESTEROL PROFILE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little information is available regarding the lipid profile in patients with PBC. One study found elevated VLDL and LDL levels as well as markedly elevated HDL levels in early (histologic) stage PBC [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/4\">",
"     4",
"    </a>",
"    ]. In later stage disease, LDL levels increased further but HDL levels fell markedly. A larger study reached somewhat similar conclusions: both LDL and total cholesterol levels increased with worsening histologic stage; the levels of HDL and apolipoprotein A-1, which is associated with HDL, were elevated at all stages but fell in patients with cirrhosis, although they may still be elevated compared to age-matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/3\">",
"     3",
"    </a>",
"    ]. Triglyceride levels were normal or slightly elevated.",
"   </p>",
"   <p>",
"    Some of the excess LDL in PBC is composed of an abnormal lipoprotein particle (lipoprotein X), which is seen in cholestatic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/5\">",
"     5",
"    </a>",
"    ]. It is rich in free cholesterol and phospholipids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/3,4,6\">",
"     3,4,6",
"    </a>",
"    ]. Lipoprotein X is believed to reduce the atherogenicity of LDL cholesterol by preventing LDL oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/7\">",
"     7",
"    </a>",
"    ]. Prolonged LDL oxidation has been demonstrated in patients with PBC, and normalizes following liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Lipoprotein (a) is another lipoprotein related to LDL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=see_link&amp;anchor=H14#H14\">",
"     \"Lipoprotein classification; metabolism; and role in atherosclerosis\", section on 'Lipoprotein(a)'",
"    </a>",
"    .) In one report, Lp(a) levels were significantly decreased in both patients with PBC and those with other chronic liver diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical implications of these dramatic lipid abnormalities include xanthomata and xanthelasmata and the possible development of atherosclerotic heart disease. Xanthelasmata (cholesterol deposits in the periorbital skin folds) and xanthomata (cholesterol deposits in tendon sheaths, bony prominences, and peripheral nerves) are classic features of PBC (",
"    <a class=\"graphic graphic_picture graphicRef67919 \" href=\"UTD.htm?23/14/23778\">",
"     picture 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .) Xanthomas but not xanthelasmas correlate with total plasma cholesterol levels. Xanthomata develop on the elbows, palms, soles, buttocks, knees, back, and chest. They are primarily seen in patients with plasma cholesterol levels above 600",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (15.6",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    for greater than three months.",
"   </p>",
"   <p>",
"    This degree of hypercholesterolemia is now uncommon in PBC. Xanthomata are not usually a major problem, and occur in less than 5 percent of patients with PBC. Affected patients may complain about the unattractive nature of these lesions, but symptoms are rare except for those who have lesions on the palms and soles. Pain and inability to use the hands usually require treatment with plasmapheresis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/8-10\">",
"     8-10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Risk of atherosclerosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The available data suggest that the risk of atherosclerosis in patients with PBC and hypercholesterolemia is low [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/2,4,11-13\">",
"     2,4,11-13",
"    </a>",
"    ]. The lipid profile in PBC is different from other lipid disorders, including the accumulation of lipoprotein X and low Lp(a) levels. It has therefore been suggested that the atherogenic potential may also be different. As a result, some recommend lipid-lowering therapy in asymptomatic patients while others do not [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several studies have shed some light on this important issue [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/2,4,11-13\">",
"     2,4,11-13",
"    </a>",
"    ]. In one study, 312 patients with PBC of different histologic stage were followed for a median of 7.4 years [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/2\">",
"     2",
"    </a>",
"    ]. When compared with an age- and sex-matched control group, there were no differences in cardiac-related mortality. A second study reported that none of 19 patients with PBC (all women, mean age 54) had evidence of coronary disease as determined by multiple noninvasive cardiac tests [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/3\">",
"     3",
"    </a>",
"    ]. A third report involving 930 patients with PBC found no increased risk of myocardial infarction, stroke or transient ischemic attack compared with 9,202 controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These studies are limited by their short duration of follow-up. If there is no increase in coronary risk, then several factors may contribute:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High levels of HDL",
"     </li>",
"     <li>",
"      Low levels of Lp(a)",
"     </li>",
"     <li>",
"      Unknown atherogenic effects of lipoprotein X",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DRUG THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of drug therapy in lowering cardiovascular morbidity and mortality in PBC is uncertain [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One patient with a plasma cholesterol concentration of 2065",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (53.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    developed hyperviscosity syndrome that was successfully reversed by plasmapheresis, which lowered the cholesterol level to 261",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (6.8",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/6\">",
"     6",
"    </a>",
"    ]. Despite therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/26/12710?source=see_link\">",
"     colestipol",
"    </a>",
"    (30",
"    <span class=\"nowrap\">",
"     g/day),",
"    </span>",
"    both the hypercholesterolemia and hyperviscosity syndrome recurred within five months.",
"   </p>",
"   <p>",
"    Another hypolipidemic agent, clofibrate, should be avoided in PBC, since it has been associated with a paradoxical elevation plasma cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/15\">",
"     15",
"    </a>",
"    ]. How this occurs and whether it is also seen with other fibric acid derivatives, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/42/43686?source=see_link\">",
"     gemfibrozil",
"    </a>",
"    , is not known.",
"   </p>",
"   <p>",
"    A four week pilot study of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    in 15 patients with early-stage PBC found it effectively reduced cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/16\">",
"     16",
"    </a>",
"    ]. However, 1 of 15 patients had to discontinue treatment because of a rise in serum ALT 2-fold above baseline. Two other patients showed ALT elevations 3-fold above the upper limit of normal at the end of treatment.",
"   </p>",
"   <p>",
"    Experience with other statins in PBC is limited to case series [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. Statin metabolism varies among the different agents. Many of the statins (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?41/20/42312?source=see_link\">",
"     lovastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/36/17993?source=see_link\">",
"     simvastatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/37/35417?source=see_link\">",
"     atorvastatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/11/10424?source=see_link\">",
"     rosuvastatin",
"    </a>",
"    ) are excreted into bile and thus levels may accumulate in PBC leading to toxicity. Thus, they should be used cautiously and avoided in patients with significant cholestasis [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PLASMAPHERESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasmapheresis has been successfully used by the authors and others to treat xanthomatous neuropathy and symptomatic xanthomas that occur on the palms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/22\">",
"     22",
"    </a>",
"    ]. Kinetic analysis in one report indicated that cholesterol synthesis exceeded excretion by 0.4",
"    <span class=\"nowrap\">",
"     g/day.",
"    </span>",
"    In comparison, a single one-volume plasma exchange can remove as much as 6.7 g of cholesterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18149/abstract/23\">",
"     23",
"    </a>",
"    ]. It is therefore not surprising that repetitive plasma exchange can cause resolution of xanthomatous deposits and associated neuropathic pain. A once-weekly one-plasma volume exchange is usually sufficient. This regimen has the added benefit of decreasing the intensity of pruritus. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=see_link\">",
"     \"Pruritus associated with cholestasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There is, at present, no evidence of increased coronary risk in patients with PBC and hypercholesterolemia but we nevertheless obtain a lipid profile.",
"     </li>",
"     <li>",
"      For patients without other known risk factors for coronary heart disease, we suggest dietary modification and exercise (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      For those with risk factors for coronary heart disease, we suggest a treatment approach similar to that of patients without PBC (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, clofibrate and probably other fibric acid derivatives should be avoided. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Drug therapy'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=see_link\">",
"       \"Treatment of lipids (including hypercholesterolemia) in secondary prevention\"",
"      </a>",
"      .) As noted above, statins should be used cautiously and avoided in patients with significant cholestasis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=see_link&amp;anchor=H28#H28\">",
"       \"Statins: Actions, side effects, and administration\", section on 'Chronic liver disease'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22536497\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;We are saddened by the death of Marshall M. Kaplan, MD, who passed away in September 2012. UpToDate wishes to acknowledge Dr. Kaplan's past work as an author for this topic, as well as his work as our Section Editor for Alcoholic and Metabolic Liver Disease.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Dickson, E, Fleming, C, Ludwig, J. Primary biliary cirrhosis. In: Progress in Liver Diseases, Vol. 6, Popper, H, Schaffner, F (Eds), Grune and Stratton, New York 1978. p.487.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/2\">",
"      Propst A, Propst T, Lechleitner M, et al. Hypercholesterolemia in primary biliary cirrhosis is no risk factor for atherosclerosis. Dig Dis Sci 1993; 38:379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/3\">",
"      Jahn CE, Schaefer EJ, Taam LA, et al. Lipoprotein abnormalities in primary biliary cirrhosis. Association with hepatic lipase inhibition as well as altered cholesterol esterification. Gastroenterology 1985; 89:1266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/4\">",
"      Crippin JS, Lindor KD, Jorgensen R, et al. Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis: what is the risk? Hepatology 1992; 15:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/5\">",
"      Su TC, Hwang JJ, Kao JH. Hypercholesterolemia in primary biliary cirrhosis. N Engl J Med 2007; 357:1561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/6\">",
"      Rosenson RS, Baker AL, Chow MJ, Hay RV. Hyperviscosity syndrome in a hypercholesterolemic patient with primary biliary cirrhosis. Gastroenterology 1990; 98:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/7\">",
"      Chang PY, Lu SC, Su TC, et al. Lipoprotein-X reduces LDL atherogenicity in primary biliary cirrhosis by preventing LDL oxidation. J Lipid Res 2004; 45:2116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/8\">",
"      Gregory WL, Game FL, Farrer M, et al. Reduced serum lipoprotein(a) levels in patients with primary biliary cirrhosis. Atherosclerosis 1994; 105:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/9\">",
"      Peters MG, Hoffnagle JH, McGarvey C, et al. Primary biliary cirrhosis: management of an unusual case with severe xanthomata by hepatic transplantation. J Clin Gastroenterol 1989; 11:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/10\">",
"      Thomas PK, Walker JG. Xanthomatous neuropathy in primary biliary cirrhosis. Brain 1965; 88:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/11\">",
"      Longo M, Crosignani A, Battezzati PM, et al. Hyperlipidaemic state and cardiovascular risk in primary biliary cirrhosis. Gut 2002; 51:265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/12\">",
"      Van Dam GM, Gips CH. Primary biliary cirrhosis in The Netherlands. An analysis of associated diseases, cardiovascular risk, and malignancies on the basis of mortality figures. Scand J Gastroenterol 1997; 32:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/13\">",
"      Sorokin A, Brown JL, Thompson PD. Primary biliary cirrhosis, hyperlipidemia, and atherosclerotic risk: a systematic review. Atherosclerosis 2007; 194:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/14\">",
"      Solaymani-Dodaran M, Aithal GP, Card T, West J. Risk of cardiovascular and cerebrovascular events in primary biliary cirrhosis: a population-based cohort study. Am J Gastroenterol 2008; 103:2784.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/15\">",
"      Schaffner F. Paradoxical elevation of serum cholesterol by clofibrate in patients with primary biliary cirrhosis. Gastroenterology 1969; 57:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/16\">",
"      Stojakovic T, Putz-Bankuti C, Fauler G, et al. Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. Hepatology 2007; 46:776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/17\">",
"      Ritzel U, Leonhardt U, N&auml;ther M, et al. Simvastatin in primary biliary cirrhosis: effects on serum lipids and distinct disease markers. J Hepatol 2002; 36:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/18\">",
"      Del Puppo M, Galli Kienle M, Crosignani A, et al. Cholesterol metabolism in primary biliary cirrhosis during simvastatin and UDCA administration. J Lipid Res 2001; 42:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/19\">",
"      Kamisako T, Adachi Y. Marked improvement in cholestasis and hypercholesterolemia with simvastatin in a patient with primary biliary cirrhosis. Am J Gastroenterol 1995; 90:1187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/20\">",
"      Kurihara T, Akimoto M, Abe K, et al. Experimental use of pravastatin in patients with primary biliary cirrhosis associated with hypercholesterolemia. Clin Ther 1993; 15:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/21\">",
"      Abu Rajab MA, Kaplan MM. Statin use in primary biliary cirrhosis: Are they safe? (abstract). Gastroenterology 2007; 132:A732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/22\">",
"      Turnberg LA, Mahoney MP, Gleeson MH, et al. Plasmaphoresis and plasma exchange in the treatment of hyperlipaemia and xanthomatous neuropathy in patients with primary biliary cirrhosis. Gut 1972; 13:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18149/abstract/23\">",
"      Kaplan AA, Halley SE, Reardon J, Sevigny J. One year's experience using a rotating filter for therapeutic plasma exchange. ASAIO Trans 1989; 35:262.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3602 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-125.39.66.147-528937E1C1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18149=[""].join("\n");
var outline_f17_46_18149=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H8\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVALENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CHOLESTEROL PROFILE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Risk of atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DRUG THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PLASMAPHERESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22536497\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3602\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3602|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?23/14/23778\" title=\"picture 1\">",
"      Xanthelasma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/45/18138?source=related_link\">",
"      Lipoprotein classification; metabolism; and role in atherosclerosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/19/23863?source=related_link\">",
"      Pruritus associated with cholestasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32314?source=related_link\">",
"      Statins: Actions, side effects, and administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/32/26122?source=related_link\">",
"      Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18150="Dextromethorphan: Drug information";
var content_f17_46_18150=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dextromethorphan: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?29/18/29988?source=see_link\">",
"    see \"Dextromethorphan: Patient drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"    see \"Dextromethorphan: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F158845\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Creo-Terpin&reg; [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; Adult Formula [OTC];",
"     </li>",
"     <li>",
"      Creomulsion&reg; for Children [OTC];",
"     </li>",
"     <li>",
"      Delsym&reg; [OTC];",
"     </li>",
"     <li>",
"      Father John's&reg; [OTC];",
"     </li>",
"     <li>",
"      Hold&reg; DM [OTC];",
"     </li>",
"     <li>",
"      Nycoff [OTC];",
"     </li>",
"     <li>",
"      PediaCare&reg; Children's Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robafen Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Children's Cough Long-Acting [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting Cough [OTC];",
"     </li>",
"     <li>",
"      Robitussin&reg; Lingering Cold Long-Acting CoughGels&reg; [OTC];",
"     </li>",
"     <li>",
"      Scot-Tussin&reg; Diabetes [OTC];",
"     </li>",
"     <li>",
"      Silphen-DM [OTC];",
"     </li>",
"     <li>",
"      Triaminic&reg; Children's Cough Long Acting [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; 44&reg; Cough Relief [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; DayQuil&reg; Cough [OTC];",
"     </li>",
"     <li>",
"      Vicks&reg; Nature Fusion&trade; Cough [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F158874\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antitussive;",
"     </li>",
"     <li>",
"      N-Methyl-D-Aspartate Receptor Antagonist",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F158848\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cough suppressant: Oral: 10-20 mg every 4 hours or 30 mg every 6-8 hours; extended release: 60 mg twice daily; maximum: 120 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F158862\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=see_link\">",
"      see \"Dextromethorphan: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cough suppressant: Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;4 years: Not for OTC use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     4-6 years (syrup): Oral: 2.5-7.5 mg every 4-8 hours; extended release is 15 mg twice daily (maximum: 30 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     6-12 years: 5-10 mg every 4 hours or 15 mg every 6-8 hours; extended release is 30 mg twice daily (maximum: 60 mg/24 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &gt;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F158849\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F158835\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, liquid filled, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robafen Cough: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Lingering Cold Long-Acting CoughGels&reg;: 15 mg [contains coconut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Liquid, oral, as hydrobromide: 15 mg/5 mL (120 mL [DSC])",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creo-Terpin&reg;: 10 mg/15 mL (120 mL) [contains ethanol 25%, tartrazine]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Scot-Tussin&reg; Diabetes: 10 mg/5 mL (118 mL) [ethanol free, gluten free, sugar free; contains propylene glycol; cherry-strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; 44&reg; Cough Relief: 10 mg/5 mL (120 mL) [contains ethanol, propylene glycol, sodium 28 mg/15 mL, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; Nature Fusion&trade; Cough: 30 mg/30 mL (240 mL) [dye free, ethanol free, gluten free; contains sodium 36 mg/30 mL; honey flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Lozenge, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hold&reg; DM: 5 mg (10s) [cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hold&reg; DM: 5 mg (10s) [original flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     PediaCare&reg; Children's Long-Acting Cough: 7.5 mg/5 mL (118 mL) [ethanol free; contains sodium 15 mg/5 mL, sodium benzoate; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vicks&reg; DayQuil&reg; Cough: 15 mg/15 mL (177 mL, 295 mL) [ethanol free; contains propylene glycol, sodium 15 mg/15 mL; citrus flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suspension, extended release, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delsym&reg;: Dextromethorphan polistirex [equivalent to dextromethorphan hydrobromide] 30 mg/5 mL (89 mL, 148 mL) [ethanol free; contains propylene glycol, sodium 7 mg/5 mL; grape flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Delsym&reg;: Dextromethorphan polistirex [equivalent to dextromethorphan hydrobromide] 30 mg/5 mL (89 mL, 148 mL) [ethanol free; contains propylene glycol, sodium 7 mg/5 mL; orange flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Syrup, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creomulsion&reg; Adult Formula: 20 mg/15 mL (120 mL) [ethanol free; contains sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Creomulsion&reg; for Children: 5 mg/5 mL (120 mL) [ethanol free; contains sodium benzoate; cherry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Father John's&reg;: 10 mg/5 mL (118 mL, 236 mL) [ethanol free]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Children's Cough Long-Acting: 7.5 mg/5 mL (118 mL) [ethanol free; contains propylene glycol, sodium 5 mg/5 mL, sodium benzoate; fruit-punch flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Robitussin&reg; Lingering Cold Long-Acting Cough: 15 mg/5 mL (118 mL) [contains ethanol 1.4%, menthol, sodium benzoate]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Silphen-DM: 10 mg/5 mL (120 mL) [strawberry flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Triaminic&reg; Children's Cough Long Acting: 7.5 mg/5 mL (118 mL) [contains benzoic acid, propylene glycol, sodium 7 mg/5 mL]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrobromide:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Nycoff: 15 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F158824\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F158836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Symptomatic relief of coughs caused by the common cold or inhaled irritants",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F158871\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <i>",
"      N",
"     </i>",
"     -methyl-D-aspartate (NMDA) antagonist",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F158878\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Benylin&reg; may be confused with Benadryl&reg;, Ventolin&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Delsym&reg; may be confused with Delfen&reg;, Desyrel",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F158873\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">",
"     Central nervous system: Confusion, excitement, irritability, nervousness, serotonin syndrome",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F158839\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Concurrent administration with or within 2 weeks of discontinuing an MAO inhibitor",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F5366785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &bull; Serotonin syndrome: Symptoms of agitation, confusion, hallucinations, hyper-reflexia, myoclonus, shivering, and tachycardia may occur with concomitant proserotonergic drugs (ie, SSRIs/SNRIs or triptans); especially with higher dextromethorphan doses.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Debilitated patients: Use with caution in patients who are sedated, debilitated or confined to a supine position.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Neonates: Some products may contain sodium benzoate which has been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates;",
"     <i>",
"      in vitro",
"     </i>",
"     and animal studies have shown that benzoate, a metabolite of benzyl alcohol, displaces bilirubin from protein binding sites; avoid use of products containing sodium benzoate in neonates.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Use with caution in atopic children. Not for OTC use in children &lt;4 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium benzoate: Some products may contain sodium benzoate may cause allergic reactions in susceptible individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tartrazine: Some products may contain tartrazine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse/misuse: Healthcare providers should be alert to problems of abuse or misuse. Abuse can cause death, brain damage, seizure, loss of consciousness, and irregular heartbeat.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Self-medication (OTC use): When used for self medication (OTC) notify healthcare provider if symptoms do not improve within 7 days, or are accompanied by fever, rash or persistent headache. Do not use for persistent or chronic cough (as with smoking, asthma, chronic bronchitis, emphysema) or if cough is accompanied by excessive phlegm unless directed to do so by healthcare provider.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F158870\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (major), CYP2E1 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2D6 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F158831\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Abiraterone Acetate: May increase the serum concentration of CYP2D6 Substrates. Management: Avoid concurrent use of abiraterone with CYP2D6 substrates that have a narrow therapeutic index whenever possible.  When concurrent use is not avoidable, monitor patients closely for signs/symptoms of toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antipsychotics: May enhance the serotonergic effect of Serotonin Modulators. This could result in serotonin syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the serotonergic effect of Dextromethorphan. This may cause serotonin syndrome.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metoclopramide: Serotonin Modulators may enhance the adverse/toxic effect of Metoclopramide. This may be manifest as symptoms consistent with serotonin syndrome or neuroleptic malignant syndrome.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: May increase the serum concentration of Dextromethorphan. Management: Avoid concurrent use of these agents when possible, unless the increased psychoactive effects of dextromethorphan are desired.  Since codeine activation is also inhibited by quinidine, codeine is unlikely to be suitable as an alternative antitussive.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: May enhance the serotonergic effect of Dextromethorphan. Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Dextromethorphan. Management: Avoid the concurrent use of dextromethorphan and SSRIs, particularly fluoxetine and paroxetine, when possible.  The risk for this interaction may persist for several weeks following discontinuation of fluoxetine or paroxetine.",
"     <b>",
"      Exceptions:",
"     </b>",
"     FluvoxaMINE.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serotonin Modulators: May enhance the adverse/toxic effect of other Serotonin Modulators. The development of serotonin syndrome may occur.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F12708268\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Maternal use of standard OTC doses of dextromethorphan when used as an antitussive during the first trimester of pregnancy has not been found to increase the risk of teratogenic effects. Dextromethorphan is metabolized in the liver via CYP2D6 and CYP3A enzymes. The activity of both enzymes is increased in the mother during pregnancy. In the fetus, CYP2D6 activity is low in the fetal liver and CYP3A4 activity is present by ~17 weeks gestation.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F158840\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Some products may contain sodium.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323103\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Robitussin CoughGels Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (20): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Robitussin Lingering CoughGels Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg (20): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (ElixSure Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/5 mL (120 mL): $4.86",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Robitussin Lingering LA Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Scot-Tussin Diabetes CF Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/5 mL (118.3 mL): $4.78",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks DayQuil Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/15 mL (354 mL): $7.66",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks Formula 44 Dry Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/15 mL (177 mL): $6.10",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Vicks Nature Fusion Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/15 mL (236 mL): $7.50",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid",
"     </b>",
"     (Wal-Tussin Cough Long Acting Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (118 mL): $6.99",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid, controlled release",
"     </b>",
"     (Delsym Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (89 mL): $8.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Liquid, controlled release",
"     </b>",
"     (Dextromethorphan Polistirex ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/5 mL (89 mL): $7.65",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Hold Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg (10): $2.39",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Lozenge",
"     </b>",
"     (Trocal Cough Suppressant Mouth/Throat)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (1): $0.18",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Strip",
"     </b>",
"     (Triaminic Long Acting Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg (14): $4.85",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Creo-Terpin Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     10 mg/15 mL (120 mL): $7.56",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Creomulsion Adult Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     20 mg/15 mL (118 mL): $2.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Creomulsion for Children Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (118 mL): $2.89",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin Childrens Cough LA Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     7.5 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Robitussin Maximum Strength Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     15 mg/5 mL (118 mL): $5.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Syrup",
"     </b>",
"     (Simply Cough Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     5 mg/5 mL (120 mL): $4.18",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F158841\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Acodin (PL);",
"     </li>",
"     <li>",
"      Akindex (BE, FR, LU, PL, PT);",
"     </li>",
"     <li>",
"      Argotussin (PL);",
"     </li>",
"     <li>",
"      Aricodil (IT);",
"     </li>",
"     <li>",
"      Arpha (DE);",
"     </li>",
"     <li>",
"      Astho-Med Husten (CH);",
"     </li>",
"     <li>",
"      Athos (MX);",
"     </li>",
"     <li>",
"      Atuxane (FR);",
"     </li>",
"     <li>",
"      Bechilar (IT);",
"     </li>",
"     <li>",
"      Benylin (NL, ZA);",
"     </li>",
"     <li>",
"      Benylin Antitusivo (ES);",
"     </li>",
"     <li>",
"      Bexin (CH);",
"     </li>",
"     <li>",
"      Bronchenolo Tosse (IT);",
"     </li>",
"     <li>",
"      Bronchosedal (BE, LU);",
"     </li>",
"     <li>",
"      Bronchydex (FR);",
"     </li>",
"     <li>",
"      Brudex (MX);",
"     </li>",
"     <li>",
"      Calmasan (CH);",
"     </li>",
"     <li>",
"      Calmerphan (CH);",
"     </li>",
"     <li>",
"      Calmerphan-L (CH);",
"     </li>",
"     <li>",
"      Calmesin-Mepha (CH);",
"     </li>",
"     <li>",
"      Canfodian (IT);",
"     </li>",
"     <li>",
"      Capsyl (BE, LU);",
"     </li>",
"     <li>",
"      Cinfatos (ES);",
"     </li>",
"     <li>",
"      Codotussyl toux seche (FR);",
"     </li>",
"     <li>",
"      Dampo Bij Droge Hoest (NL);",
"     </li>",
"     <li>",
"      Darolan Hoestprikkeldempend (NL);",
"     </li>",
"     <li>",
"      Daromefan (NL);",
"     </li>",
"     <li>",
"      Delsym (IE);",
"     </li>",
"     <li>",
"      Destrometorfano Bromidrato (IT);",
"     </li>",
"     <li>",
"      Dexatussin (PL);",
"     </li>",
"     <li>",
"      Dexir (BE, FR);",
"     </li>",
"     <li>",
"      Dexofan (DK);",
"     </li>",
"     <li>",
"      Dextphan (JP);",
"     </li>",
"     <li>",
"      Dextrogel Oral (CH);",
"     </li>",
"     <li>",
"      Dextromephar (BE);",
"     </li>",
"     <li>",
"      Dextrometorfano Fabra (AR);",
"     </li>",
"     <li>",
"      Dextrotos (AR);",
"     </li>",
"     <li>",
"      Emedrin N (CH);",
"     </li>",
"     <li>",
"      Fluprim (IT);",
"     </li>",
"     <li>",
"      Formitrol (IT);",
"     </li>",
"     <li>",
"      Formulatus (ES);",
"     </li>",
"     <li>",
"      Humex (BE, ES);",
"     </li>",
"     <li>",
"      Hustenstiller-ratiopharm (DE);",
"     </li>",
"     <li>",
"      Hustep (JP);",
"     </li>",
"     <li>",
"      Kibon S (JP);",
"     </li>",
"     <li>",
"      Lagun (FI);",
"     </li>",
"     <li>",
"      Methorcon (JP);",
"     </li>",
"     <li>",
"      Metorfan (IT);",
"     </li>",
"     <li>",
"      NeoTussan (DE, LU);",
"     </li>",
"     <li>",
"      Nodex (FR);",
"     </li>",
"     <li>",
"      Notuxal (BE);",
"     </li>",
"     <li>",
"      Nucosef (AU);",
"     </li>",
"     <li>",
"      Pectofree (BE);",
"     </li>",
"     <li>",
"      Pulmofor (CH);",
"     </li>",
"     <li>",
"      Rami Dextromethorfan Hoestdrank (NL);",
"     </li>",
"     <li>",
"      Resilar (FI);",
"     </li>",
"     <li>",
"      Rhinathiol (FR, LU);",
"     </li>",
"     <li>",
"      Rivodex (CH);",
"     </li>",
"     <li>",
"      Rivolyn (CH);",
"     </li>",
"     <li>",
"      Robitussin (AU, ES, IE, PL);",
"     </li>",
"     <li>",
"      Romilar (AR, BE, ES, LU, MX);",
"     </li>",
"     <li>",
"      Sanabronchiol (IT);",
"     </li>",
"     <li>",
"      Sebrane (FR);",
"     </li>",
"     <li>",
"      Siepex (ES);",
"     </li>",
"     <li>",
"      Sisaal (JP);",
"     </li>",
"     <li>",
"      Soludril Toux seches (LU);",
"     </li>",
"     <li>",
"      Strepsils (AU);",
"     </li>",
"     <li>",
"      Tesafilm (MX);",
"     </li>",
"     <li>",
"      Tip (ES);",
"     </li>",
"     <li>",
"      Tosfriol (ES);",
"     </li>",
"     <li>",
"      Tosion retard (NL);",
"     </li>",
"     <li>",
"      Tossoral (IT);",
"     </li>",
"     <li>",
"      Touxium Antitussivum (BE, LU);",
"     </li>",
"     <li>",
"      Trimpus (JP);",
"     </li>",
"     <li>",
"      Tusitinas (ES);",
"     </li>",
"     <li>",
"      Tusorama (DE, ES);",
"     </li>",
"     <li>",
"      Tuss Hustenstiller (DE);",
"     </li>",
"     <li>",
"      Tussal Antitussicom (PL);",
"     </li>",
"     <li>",
"      Tussidex (PL);",
"     </li>",
"     <li>",
"      Tussidril (ES);",
"     </li>",
"     <li>",
"      Tussidrill (PL);",
"     </li>",
"     <li>",
"      Tussinol (AU);",
"     </li>",
"     <li>",
"      Tussipect (BE, LU);",
"     </li>",
"     <li>",
"      Tussycalm (IT);",
"     </li>",
"     <li>",
"      Tuxium (FR);",
"     </li>",
"     <li>",
"      Valatux (IT);",
"     </li>",
"     <li>",
"      Valdatos (ES);",
"     </li>",
"     <li>",
"      Vicks (CH, FR);",
"     </li>",
"     <li>",
"      Vicks Hustensirup mit Dextromethorphan (CH);",
"     </li>",
"     <li>",
"      Vicks sirop contre la toux, avec dextromethorphane (CH);",
"     </li>",
"     <li>",
"      Vicks Tosse Pastiglie (IT);",
"     </li>",
"     <li>",
"      Vicks Tosse Sedativo (IT);",
"     </li>",
"     <li>",
"      Vicks Vaposiroop (NL);",
"     </li>",
"     <li>",
"      Vicks Vaposyrup (BE);",
"     </li>",
"     <li>",
"      Wick Formel 44 Husten-Pastillen S (AT, DE);",
"     </li>",
"     <li>",
"      Wick Formel 44 Hustenstiller (AT, DE);",
"     </li>",
"     <li>",
"      Wick Formula 44 Plus S (PL)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F158827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Decreases the sensitivity of cough receptors and interrupts cough impulse transmission by depressing the medullary cough center through sigma receptor stimulation; structurally related to codeine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F158838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: Antitussive: 15-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: &le;6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic via demethylation via CYP2D6 to dextrorphan (active); CYP3A4 and CYP3A5 form smaller amounts of 3-hydroxy and 3-methoxy derivatives",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Dextromethorphan: Extensive metabolizers: 2-4 hours; poor metabolizers: 24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily in urine as metabolites",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Moeller KE, Lee KC, and Kissack JC, &ldquo;Urine Drug Screening: Practical Guide for Clinicians,&rdquo;",
"      <i>",
"       Mayo Clin Proc",
"      </i>",
"      , 2008, 83(1):66-76.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/46/18150/abstract-text/18174009/pubmed\" id=\"18174009\" target=\"_blank\">",
"        18174009",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schier J, &ldquo;Avoid Unfavorable Consequences: Dextromethorphan Can Bring About a False-Positive Phencyclidine Urine Drug Screen,&rdquo;",
"      <i>",
"       J Emerg Med",
"      </i>",
"      , 2000, 18(3):379-81.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/46/18150/abstract-text/10787303/pubmed\" id=\"10787303\" target=\"_blank\">",
"        10787303",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Schwartz AR, Pizon AF, and Brooks DE, &ldquo;Dextromethorphan-Induced Serotonin Syndrome,&rdquo;",
"      <i>",
"       Clin Toxicol (Phila)",
"      </i>",
"      , 2008, 46(8):771-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/46/18150/abstract-text/19238739/pubmed\" id=\"19238739\" target=\"_blank\">",
"        19238739",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Siu A and Drachtman R, &ldquo;Dextromethorphan: A Review of N-methyl-D-aspartate Receptor Antagonist in the Management of Pain,&rdquo;",
"      <i>",
"       CNS Drug Rev",
"      </i>",
"      , 2007, 13(1):96-106.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?17/46/18150/abstract-text/17461892/pubmed\" id=\"17461892\" target=\"_blank\">",
"        17461892",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8893 Version 40.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-41.78.124.10-D5AC4AD6BF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18150=[""].join("\n");
var outline_f17_46_18150=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158845\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158874\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158848\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158862\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158849\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158835\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158824\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158836\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158871\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158878\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158873\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158839\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5366785\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158870\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158831\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12708268\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158840\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323103\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158841\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158827\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F158838\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8893\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8893|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?29/18/29988?source=related_link\">",
"      Dextromethorphan: Patient drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/21/34132?source=related_link\">",
"      Dextromethorphan: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18151="Acute and early HIV infection: Pathogenesis and epidemiology";
var content_f17_46_18151=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Acute and early HIV infection: Pathogenesis and epidemiology",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18151/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18151/contributors\">",
"     Paul E Sax, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18151/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18151/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18151/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18151/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/46/18151/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 13, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1985, the first description of acute human immunodeficiency virus (HIV) infection, a \"mononucleosis-like\" illness, was published based upon the clinical records of 12 men with documented seroconversion to HIV during the preceding six months; 11 of these individuals experienced a remarkably similar illness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/1\">",
"     1",
"    </a>",
"    ]. Since that time, larger studies have described the clinical and laboratory features of acute and early HIV infection.",
"   </p>",
"   <p>",
"    With the advent of more specific diagnostic testing, particularly HIV RNA detection, and more active drug regimens, early aggressive therapy during early HIV infection has become an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=see_link\">",
"     \"Techniques and interpretation of HIV-1 RNA quantitation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pathogenesis and epidemiology of acute and early HIV will be reviewed here. The clinical manifestations, diagnosis, and treatment of early HIV infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=see_link\">",
"     \"Acute and early HIV infection: Clinical manifestations and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=see_link\">",
"     \"Acute and early HIV infection: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152751881\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different terms, including acute, recent, primary, and early HIV infection, have been used in the literature to refer to variable intervals following initial infection with the virus. In this topic, we use the term &ldquo;early HIV infection&rdquo; to refer to the approximate six-month period following HIV acquisition. We use the term &ldquo;acute HIV infection&rdquo; to refer to symptomatic early infection, as this reflects common usage in clinical care. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV has several targets including dendritic cells, macrophages, and CD4+ T cells.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Target cells",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV-1 most often enters the host through the anogenital mucosa. The viral envelope protein, glycoprotein (GP)-120, binds to the CD4 molecule on dendritic cells. Interstitial dendritic cells are found in cervicovaginal epithelium as well as tonsillar and adenoidal tissue, which may serve as initial target cells in infection transmitted via genital-oral sex [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Newly acquired HIV infection is more commonly due to transmission of macrophage tropic rather than T cell tropic viruses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/3\">",
"     3",
"    </a>",
"    ]. Viral entry into these cells is mediated by different coreceptors. In order to enter macrophages, GP-120 must bind to the chemokine receptor CCR5 as well as CD4 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Macrophage tropic viruses are designated as R5 in comparison to T cell tropic viruses, which are called X4, based upon the CXCR4 receptor on these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients homozygous for a deletion in CCR5 are relatively resistant to R5 infection, but cases of X4 infection have rarely been reported in these individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/6-9\">",
"     6-9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV infected cells fuse with CD4+ T cells, leading to spread of the virus. HIV is detectable in regional lymph nodes within two days of mucosal exposure and in plasma within another three days [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"     2",
"    </a>",
"    ]. Once virus enters the blood, there is widespread dissemination to organs such as the brain, spleen, and lymph nodes.",
"   </p>",
"   <p>",
"    The intestinal mucosa is also a primary target during initial infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Massive CD4 T-cell depletion during acute infection has been demonstrated with simian immunodeficiency virus (SIV) in rhesus macaques [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Both studies documented that destruction occurred preferentially in CD4+ memory T cells, which may result from direct infection as well as through apoptosis. This can lead to an early and disproportionate loss of CD4+ T cells in the gastrointestinal compartment, compared to peripheral blood [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/14\">",
"     14",
"    </a>",
"    ]. It has also been proposed that microbial translocation, due to changes in the gut mucosal barrier, may be the etiology of chronic immune activation in HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/15,16\">",
"     15,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Viremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies in primates suggest viral penetration of mucosal epithelium, followed by infection of submucosal CD4+ T cells, dendritic cells, and macrophages with subsequent spread to lymph nodes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/17\">",
"     17",
"    </a>",
"    ] and ultimately, plasma. Viremia was documented between 5 to 30 days after experimental intravaginal HIV exposure.",
"   </p>",
"   <p>",
"    HIV RNA levels rapidly increase from the earliest quantifiable measure to a peak level that usually coincides with seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. However, a period of low-level viremia preceding ramp-up viremia, may be more common than originally thought. A study of serial samples from patients with confirmed early HIV infection was performed to determine if low levels of viremia were present in samples that were negative by prior quantitative PCR [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/20\">",
"     20",
"    </a>",
"    ]. On retesting with a sensitive qualitative reverse transcriptase PCR assay with sensitivity of 4",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    23 of 69 samples were subsequently positive. These specimens preceded the first sample with &gt;100",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    by 9 to 25 days. Whether blood is infectious at this low level of concentration is not known.",
"   </p>",
"   <p>",
"    The HIV DNA level in peripheral blood mononuclear cells provides an estimate of the cellular HIV reservoir, which is established soon after infection. In one study of 163 patients who did not start immediate antiretroviral therapy after diagnosis of acute infection, the HIV DNA level and initial CD4 cell count were found to be independent predictors of disease progression [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Cellular immune response",
"    </span>",
"    &nbsp;&mdash;&nbsp;At the time of initial infection with HIV, patients have a large number of susceptible CD4+ T cells and no HIV-specific immune response. Viral replication is therefore rapid; plasma HIV RNA levels may climb to more than 10(7)",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    and p24 antigen levels may exceed 100",
"    <span class=\"nowrap\">",
"     pg/mL.",
"    </span>",
"   </p>",
"   <p>",
"    Concomitant",
"    with the evolution of HIV specific immunity, primarily due to the emergence of virus-specific CD8+ cytotoxic T lymphocytes, plasma RNA levels fall precipitously by 2 to 3 logs, and symptoms of the acute retroviral syndrome resolve. In the absence of antiretroviral therapy, plasma HIV RNA levels will stabilize at an individual's given \"set-point\" within six months of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/22\">",
"     22",
"    </a>",
"    ]. The host factors, virus factors, and pharmacologic interventions, which determine this set point, are active issues for ongoing investigations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A few HIV-positive individuals may, even in the absence of antiretroviral therapy, retain normal CD4 counts and low or undetectable plasma viremia. Those with persistent viral suppression are referred to as &ldquo;elite controllers&rdquo;. A large study from France demonstrated that this clinical phenotype was quite rare [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/23\">",
"     23",
"    </a>",
"    ]. These individuals are distinguished from regular and rapid progressors by the persistence of HIV-specific T-helper cell proliferative responses. In one model, these proliferative responses allow for ongoing HIV-specific cytotoxic T lymphocyte activity and hence containment of plasma viremia. However, it is not clear whether these HIV immune responses directly cause, or alternatively, are the result of HIV control. Some research suggests that initiation of aggressive combination antiviral therapy during acute infection protects activated HIV-specific T helper cells from infection by HIV and thereby preserves the HIV-specific cytotoxic T lymphocyte response to virally infected cells &mdash; a situation analogous to the long-term nonprogressors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Studies of T cell responses in early HIV infection help to delineate how early therapy might improve clinical outcomes. In one study, patients with early HIV infection who were identified early in the course of their acute disease demonstrated a 10- to 20-fold increase in the proportion of highly activated (CD38+) and proliferating (Ki-67+) CD4 T cells that expressed CCR5 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/24\">",
"     24",
"    </a>",
"    ]. CD4 T cells that produced interferon gamma in response to HIV antigens were readily detected in this patient subset. However, in patients with early HIV infection who presented later in their clinical course, antigen-specific CD4+ T cells could not be readily detected. This observation coincided with lower frequencies of activated and proliferating T cells, suggesting that apoptosis and cytopathic infection with HIV leads to their rapid decline. Regulatory T cells may also play a role in suppressing HIV-specific CD4 T cell responses in early infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Preservation of the immune response to HIV may also shorten the duration of symptoms associated with acute infection, prevent dissemination of virus to other organs, and establish a lower virologic \"set-point.\" Despite these potential benefits, eradication of virus seems unlikely with currently available agents, as studies consistently show that replication-competent HIV may be recovered even from patients with completely suppressed viral loads [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/26\">",
"     26",
"    </a>",
"    ]. In addition, patients with extremely low levels of virus after prolonged virologic suppressions still experience virologic rebound when treatment is stopped [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/27\">",
"     27",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    This concept was well-illustrated in a case report of an infant girl who was diagnosed with HIV infection at birth after her mother had primary seroconversion two weeks earlier [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/28\">",
"     28",
"    </a>",
"    ]. The baby was initiated on combination antiretroviral therapy within one week of birth. Antiretroviral therapy led to full suppression of HIV viremia, undetectable HIV-specific antibodies, and lack of detection of proviral DNA in peripheral blood mononuclear cells and tonsillar tissue. In light of these findings and her strong HIV-specific T cell proliferative responses, antiviral therapy was stopped. Within one month, the CD4 count dropped from 3674 to",
"    <span class=\"nowrap\">",
"     2174/microL",
"    </span>",
"    and HIV plasma viremia rose to 46,000",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Genetic susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cohorts of individuals who are highly exposed (injection drug users or commercial sex workers) but who remain HIV-seronegative have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/29\">",
"     29",
"    </a>",
"    ]. A nested case-control study of 266 HIV-seropositive patients and 532 seronegative controls was conducted to examine whether any of nine candidate host genes may play a role in susceptibility to HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/30\">",
"     30",
"    </a>",
"    ]. Self-reported risk behaviors were analyzed from data collected at semi-annual visits. Four single-nucleotide polymorphisms (CCR-2, CCR5, MIP1A, and IL2) were significantly associated with HIV infection susceptibility in different genetic models.",
"   </p>",
"   <p>",
"    The most extensively studied of these genetic factors is the C-C chemokine receptor 5 (CCR5), a major coreceptor for HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/5\">",
"     5",
"    </a>",
"    ]. CCR5 (delta) 32 is an allele that contains a 32-base pair deletion and codes for a nonfunctional coreceptor. CCR5 (delta) 32 homozygotes (people who inherited the allele from both parents) are highly resistant to HIV infection. Patients who are heterozygous for the 32-base pair deletion can acquire HIV infection, but have a slower rate of progression. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=see_link&amp;anchor=H5#H5\">",
"     \"Factors affecting HIV progression\", section on 'Rate of progression'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152753516\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptomatic acute HIV infection has been reported in all major risk categories including men who have sex with men (MSM), injection drug users, blood product recipients, and healthcare workers with a needle-stick exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/31\">",
"     31",
"    </a>",
"    ]. Transmission of HIV during early infection is correlated with unprotected anal intercourse, the number of sexual contacts, and high rates of acute sexually transmitted diseases in MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152753523\">",
"    <span class=\"h2\">",
"     Symptomatic versus subclinical disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is difficult to determine the incidence of symptomatic versus subclinical early HIV infection for a number of reasons:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      It is often not possible to precisely define the time of seroconversion",
"     </li>",
"     <li>",
"      The clinical symptoms are nonspecific",
"     </li>",
"     <li>",
"      Not all febrile illnesses retrospectively identified during seroconversion will represent early HIV infection",
"     </li>",
"     <li>",
"      Patients with asymptomatic early infection often do not seek medical attention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these caveats, the majority of patients with early HIV infection appear to be symptomatic. In a retrospective case-control study, 39 homosexual men who seroconverted were compared to 26 homosexual men who were seronegative during a six-month period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/33\">",
"     33",
"    </a>",
"    ]. Ninety-two percent of the men who seroconverted reported a clinical illness during the six-month interval compared to 40 percent of controls; the average duration of symptoms was 10 days longer in seroconverters and 87 percent sought medical attention. While the calculated lower limit of incidence of symptomatic acute HIV infection from this study is 53 percent based upon 40 percent of controls reporting an illness, the incidence is probably closer to the 92 percent given the distinctive nature of the syndrome reported by seroconverters.",
"   </p>",
"   <p>",
"    In another study of seroconverters, identified through a surveillance program in which HIV testing was performed over six months, 20 of 23 (87 percent) individuals recalled symptoms consistent with the acute retroviral syndrome during the six-month interval containing their seroconversion. Nineteen of these patients felt ill enough to seek medical attention &mdash; 48 percent from their primary care physician, 31 percent from an emergency department, and 21 percent from a walk-in clinic [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is evidence that the presence of severe symptoms during acute infection predicts more rapid clinical progression to acquired immunodeficiency syndrome AIDS [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/35,36\">",
"     35,36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H152753530\">",
"    <span class=\"h2\">",
"     Transmitted drug resistance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies of early HIV infection have highlighted the growing importance of transmitted drug resistance:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective analysis of primary drug resistance in plasma samples from 377 patients with early HIV from May 1995 through June 2000 in 10 North American cities revealed an increasing incidence of both high-level single drug and multidrug resistance [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/37\">",
"       37",
"      </a>",
"      ]. High-level resistance by phenotype testing to any drug significantly increased from 3.4 percent in the years 1995 to 1998 to 12.4 percent in 1999 to 2000; during these same time periods high-level multidrug resistance rose from 1.1 to 6.2 percent. The time required for viral suppression after beginning antiretroviral therapy was longer and the time to virologic failure shorter among patients with drug-resistant virus at the start.",
"     </li>",
"     <li>",
"      In an earlier retrospective cohort of patients from five metropolitan areas in the United States, a greater than 10-fold reduction in susceptibility to one or more drugs was observed in 2 percent of patients with early HIV infection and a 2.5 to 10-fold reduction in 26 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 80 patients with early HIV referred to a well-known AIDS research center found resistance phenotypes in 16 percent, including to protease inhibitors (PI) in two patients and multidrug resistance in three [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/39\">",
"       39",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      When resistance testing was performed in 82 consecutive patients with early HIV-1 infection from 1996 through July, 1998, in Geneva,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      resistance was detected in 9 percent and resistance to protease inhibitors (RTI) in 4 percent (two of these patients had concomitant resistance to reverse-transcriptase inhibitors) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/40\">",
"       40",
"      </a>",
"      ]. One patient had an isolate with 12 mutations including resistance to multiple RTI and PI.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As in other settings where HIV is newly diagnosed, it is recommended that all patients with documented early HIV infection also undergo resistance testing after the diagnosis has been established.",
"   </p>",
"   <p>",
"    With the observed rise in non-Clade B subtypes in the United States, it may be clinically useful to note patterns of altered acquisition of HIV-I variants. One study from Kenya raises questions about the nature of the infecting virus in men and women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/41\">",
"     41",
"    </a>",
"    ]. Women were more likely to be infected with diverse variants of HIV in comparison to men; both groups acquired the virus from heterosexual contact and had similar frequency of sexual intercourse and sexually transmitted diseases. In samples tested from before seroconversion the difference was quite striking; 20 of 32 women had multiple variants of the virus compared to 0 of 10 for the men.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Infectivity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with early HIV infection are highly contagious to others, given the typical transiently high viral loads seen in early HIV infection. Blood HIV viral load correlates with the risk of transmission of HIV. In men with acute HIV infection, the viral load in semen appears to follow a similar pattern to that seen in blood, with the highest levels occurring at approximately 20 days after infection or six days after the onset of symptoms for those with an acute retroviral syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link&amp;anchor=H4#H4\">",
"     \"The stages and natural history of HIV infection\", section on 'Viral transmission'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One model of heterosexual infection suggested that in the absence of other sexually transmitted diseases, men could be expected to infect 7 to 24 percent of susceptible female partners during the first two months of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/42\">",
"     42",
"    </a>",
"    ]. However, another study suggested that accurate estimates of transmission rates at the population level have been limited by imprecise definitions of acute HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Pooled HIV RNA testing has been proposed as a method to detect acute HIV infection in persons with negative serologic assays; focused interventions in high prevalence geographical areas may be cost-effective and decrease the risk of transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/44\">",
"     44",
"    </a>",
"    ]. Use of the combined antibody-antigen test is also helpful in the diagnosis of patients before seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18151/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21632630\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV has several targets, including dendritic cells, macrophages, and CD4+ T cells. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Target cells'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      HIV RNA levels rapidly increase from the earliest quantifiable measure to a peak level that usually coincides with seroconversion. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Viremia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      At the time of initial infection, patients have a large number of susceptible CD4+ T cells and no HIV-specific immune responses. Viral replication is therefore rapid and plasma viremia is extraordinarily high. However, when virus-specific CD8+ cytotoxic T lymphocytes emerge, plasma viremia levels fall precipitously. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Cellular immune response'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic acute HIV infection has been reported in all major risk categories including men who have sex with men (MSM), injection drug users, and healthcare workers with a needle-stick exposure. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with early HIV infection are highly contagious to others, given the typical high viral loads that are seen transiently in early HIV infection. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Infectivity'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/1\">",
"      Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet 1985; 1:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/2\">",
"      Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/3\">",
"      Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/4\">",
"      Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272:1955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/5\">",
"      Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/6\">",
"      Paxton WA, Martin SR, Tse D, et al. Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat Med 1996; 2:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/7\">",
"      Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/8\">",
"      Biti R, Ffrench R, Young J, et al. HIV-1 infection in an individual homozygous for the CCR5 deletion allele. Nat Med 1997; 3:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/9\">",
"      O'Brien TR, Winkler C, Dean M, et al. HIV-1 infection in a man homozygous for CCR5 delta 32. Lancet 1997; 349:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/10\">",
"      Centlivre M, Sala M, Wain-Hobson S, Berkhout B. In HIV-1 pathogenesis the die is cast during primary infection. AIDS 2007; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/11\">",
"      Nilsson J, Kinloch-de-Loes S, Granath A, et al. Early immune activation in gut-associated and peripheral lymphoid tissue during acute HIV infection. AIDS 2007; 21:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/12\">",
"      Mattapallil JJ, Douek DC, Hill B, et al. Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection. Nature 2005; 434:1093.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/13\">",
"      Li Q, Duan L, Estes JD, et al. Peak SIV replication in resting memory CD4+ T cells depletes gut lamina propria CD4+ T cells. Nature 2005; 434:1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/14\">",
"      Kotler DP. HIV infection and the gastrointestinal tract. AIDS 2005; 19:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/15\">",
"      Haynes BF. Gut microbes out of control in HIV infection. Nat Med 2006; 12:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/16\">",
"      Brenchley JM, Price DA, Schacker TW, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006; 12:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/17\">",
"      Nowak MA, Lloyd AL, Vasquez GM, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997; 71:7518.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/18\">",
"      Fiebig EW, Wright DJ, Rawal BD, et al. Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 2003; 17:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/19\">",
"      Little SJ, McLean AR, Spina CA, et al. Viral dynamics of acute HIV-1 infection. J Exp Med 1999; 190:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/20\">",
"      Fiebig EW, Heldebrant CM, Smith RI, et al. Intermittent low-level viremia in very early primary HIV-1 infection. J Acquir Immune Defic Syndr 2005; 39:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/21\">",
"      Goujard C, Bonarek M, Meyer L, et al. CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1 infection in untreated patients. Clin Infect Dis 2006; 42:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/22\">",
"      Quinn TC. Acute primary HIV infection. JAMA 1997; 278:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/23\">",
"      Grabar S, Selinger-Leneman H, Abgrall S, et al. Prevalence and comparative characteristics of long-term nonprogressors and HIV controller patients in the French Hospital Database on HIV. AIDS 2009; 23:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/24\">",
"      Zaunders JJ, Munier ML, Kaufmann DE, et al. Early proliferation of CCR5(+) CD38(+++) antigen-specific CD4(+) Th1 effector cells during primary HIV-1 infection. Blood 2005; 106:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/25\">",
"      Kared H, Leli&egrave;vre JD, Donkova-Petrini V, et al. HIV-specific regulatory T cells are associated with higher CD4 cell counts in primary infection. AIDS 2008; 22:2451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/26\">",
"      Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 1997; 278:1295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/27\">",
"      Chun TW, Justement JS, Murray D, et al. Rebound of plasma viremia following cessation of antiretroviral therapy despite profoundly low levels of HIV reservoir: implications for eradication. AIDS 2010; 24:2803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/28\">",
"      Vigan&ograve; A, Trabattoni D, Schneider L, et al. Failure to eradicate HIV despite fully successful HAART initiated in the first days of life. J Pediatr 2006; 148:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/29\">",
"      Telenti A, Ioannidis JP. Susceptibility to HIV infection--disentangling host genetics and host behavior. J Infect Dis 2006; 193:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/30\">",
"      Shrestha S, Strathdee SA, Galai N, et al. Behavioral risk exposure and host genetics of susceptibility to HIV-1 infection. J Infect Dis 2006; 193:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/31\">",
"      Tindall B, Cooper DA, Donovan B, Penny R. Primary human immunodeficiency virus infection. Clinical and serologic aspects. Infect Dis Clin North Am 1988; 2:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/32\">",
"      Pao D, Fisher M, Hu&eacute; S, et al. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS 2005; 19:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/33\">",
"      Tindall B, Barker S, Donovan B, et al. Characterization of the acute clinical illness associated with human immunodeficiency virus infection. Arch Intern Med 1988; 148:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/34\">",
"      Schacker T, Collier AC, Hughes J, et al. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996; 125:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/35\">",
"      Pedersen C, Lindhardt BO, Jensen BL, et al. Clinical course of primary HIV infection: consequences for subsequent course of infection. BMJ 1989; 299:154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/36\">",
"      Dorrucci M, Rezza G, Vlahov D, et al. Clinical characteristics and prognostic value of acute retroviral syndrome among injecting drug users. Italian Seroconversion Study. AIDS 1995; 9:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/37\">",
"      Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002; 347:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/38\">",
"      Little SJ, Daar ES, D'Aquila RT, et al. Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999; 282:1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/39\">",
"      Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA 1999; 282:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/40\">",
"      Yerly S, Kaiser L, Race E, et al. Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999; 354:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/41\">",
"      Long EM, Martin HL Jr, Kreiss JK, et al. Gender differences in HIV-1 diversity at time of infection. Nat Med 2000; 6:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/42\">",
"      Pilcher CD, Tien HC, Eron JJ Jr, et al. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis 2004; 189:1785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/43\">",
"      Brown AE, Gifford RJ, Clewley JP, et al. Phylogenetic reconstruction of transmission events from individuals with acute HIV infection: toward more-rigorous epidemiological definitions. J Infect Dis 2009; 199:427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/44\">",
"      Miller WC, Leone PA, McCoy S, et al. Targeted testing for acute HIV infection in North Carolina. AIDS 2009; 23:835.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18151/abstract/45\">",
"      Eshleman SH, Khaki L, Laeyendecker O, et al. Detection of individuals with acute HIV-1 infection using the ARCHITECT HIV Ag/Ab Combo assay. J Acquir Immune Defic Syndr 2009; 52:121.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3752 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-E57427EB1A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18151=[""].join("\n");
var outline_f17_46_18151=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21632630\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H152751881\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Target cells",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Viremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Cellular immune response",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Genetic susceptibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152753516\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152753523\">",
"      Symptomatic versus subclinical disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H152753530\">",
"      Transmitted drug resistance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Infectivity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21632630\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/7/43129?source=related_link\">",
"      Acute and early HIV infection: Clinical manifestations and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/17/22808?source=related_link\">",
"      Acute and early HIV infection: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/39/24186?source=related_link\">",
"      Factors affecting HIV progression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39623?source=related_link\">",
"      Techniques and interpretation of HIV-1 RNA quantitation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18152="Variable decelerations";
var content_f17_46_18152=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F86060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F86060&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 620px\">",
"   <div class=\"ttl\">",
"    Variable decelerations",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 600px; height: 276px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Recurrent vaariable decelerations with absent to&nbsp;minimal variability.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce K Young, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18152=[""].join("\n");
var outline_f17_46_18152=null;
var title_f17_46_18153="Anticoagulation during pregnancy";
var content_f17_46_18153=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Anticoagulation during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Jess Mandel, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     William H Gaasch, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Kenneth A Bauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Lawrence LK Leung, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Charles J Lockwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18153/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/46/18153/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 26, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H883650\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians are occasionally faced with the dilemma of managing pregnant patients who require ongoing anticoagulation for the prophylaxis or treatment of thrombotic complications. Examples include women with mechanical heart valves, venous thromboembolism (VTE) immediately prior to or during pregnancy, heart failure, and symptomatic antiphospholipid antibody syndrome (see appropriate topic reviews).",
"   </p>",
"   <p>",
"    Strategies to maintain therapeutic anticoagulation while avoiding maternal or fetal harm due to antithrombotic agents are based largely upon retrospective data because ethical and legal considerations make large prospective trials among pregnant women difficult to conduct.",
"   </p>",
"   <p>",
"    This topic review will describe the experience with major antithrombotic agents in pregnant women and discuss the management of several common conditions that require anticoagulation during pregnancy. General issues related to the clinical use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Due to the unique nature of managing pregnant women with mechanical prosthetic valves, anticoagulation in this setting is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Newer oral anticoagulants including direct thrombin inhibitors and factor Xa inhibitors are",
"    <strong>",
"     contraindicated",
"    </strong>",
"    during pregnancy and breastfeeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H7#H7\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Direct thrombin inhibitors'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link&amp;anchor=H15#H15\">",
"     \"Anticoagulants other than heparin and warfarin\", section on 'Factor Xa inhibitors'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COMMON ANTITHROMBOTIC AGENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (UFH) and low-molecular-weight heparin (LMWH) are the antithrombotic agents most commonly considered for use in pregnant women. Oral anticoagulants (OACs), usually",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , are generally not used during pregnancy for the reasons outlined below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Warfarin",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is mediated by interference with the vitamin K-dependent gamma-carboxylation of coagulation factors II, VII, IX, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/1\">",
"     1",
"    </a>",
"    ]. This results in the synthesis of immunologically detectable but biologically inactive forms of these coagulation proteins. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The anticoagulant effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    is delayed until the normal clotting factors are cleared from the circulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/2\">",
"     2",
"    </a>",
"    ]. During the first few days of warfarin therapy, the prolongation of the prothrombin time (PT) mainly reflects the depression of factor VII, which has a half-life of five to seven hours. This does not represent adequate anticoagulation, because the intrinsic and common clotting pathways remain intact until factors II, IX, and X are sufficiently reduced, which takes about five days with adequate dosing (",
"    <a class=\"graphic graphic_figure graphicRef79998 \" href=\"UTD.htm?23/62/24558\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    is the long-term anticoagulant of choice in nonpregnant patients, but its great disadvantage in pregnancy is that it freely crosses the placental barrier because of its low molecular weight and can harm the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. For this reason, the drug is classified by the United States Food and Drug Administration (FDA) as pregnancy category X (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Adverse fetal effects from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    may result from the teratogenicity of the drug and its propensity to cause bleeding in the fetus.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Teratogenic effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is convincing evidence that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    administration is potentially teratogenic. Embryopathy is most likely with exposure during the sixth to ninth weeks of gestation, but toxicity after this period is still possible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. Exposure is also associated with higher rates of spontaneous abortion and stillbirth [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. The teratogenic effect appears to be dose related, with doses less than 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    providing the highest margin of safety [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common developmental abnormalities affect bone and cartilage; these simulate chondromalacia punctata, with stippled epiphyses and nasal and limb hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/13\">",
"     13",
"    </a>",
"    ]. The mechanism of this type of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    teratogenicity has not been established, but may be related to the drug's interference with the post-translational modification of calcium-binding proteins that are important for the normal growth and development of bony structures [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/14\">",
"     14",
"    </a>",
"    ]. As an example, osteocalcin carboxylation in human subjects is a vitamin K-dependent process, and circulating osteocalcin is structurally altered by warfarin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=see_link\">",
"     \"Vitamin K and the synthesis of gamma carboxyglutamic acid\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Less well-documented are reports of central nervous system (CNS) abnormalities (including optic atrophy, microcephaly, mental retardation, spasticity, and hypotonia) associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    use at any stage during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/3,16-19\">",
"     3,16-19",
"    </a>",
"    ]. This complication may be related to fetal anticoagulation leading to CNS hemorrhage. Fetal or neonatal hemorrhage is a concern when warfarin is administered in the second and third trimesters; however, this complication has rarely been observed [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/11,20-23\">",
"     11,20-23",
"    </a>",
"    ]. The risk is thought to be greatest during and immediately after delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/18,19\">",
"     18,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The precise risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    embryopathy is unknown. While different series have reported widely ranging incidences among fetuses exposed to warfarin between the sixth and twelfth weeks of gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/13\">",
"     13",
"    </a>",
"    ], the best overall estimate of the risk is less than 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study, for example, found no congenital abnormalities in 46 women with prosthetic valves who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    during the first trimester [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/21\">",
"     21",
"    </a>",
"    ]. However, other reports have not found such a benign outcome, primarily in patients taking warfarin between the six and twelfth weeks of pregnancy. As an example, the following findings were noted in report of 72 pregnancies in women with valve prostheses [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Virtually no embryopathic events occurred in the 23 pregnancies in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was discontinued by the sixth week of gestation and not restarted until after the twelfth week.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       Warfarin",
"      </a>",
"      embryopathy occurred in 25 percent of the 12 pregnancies in which warfarin was not stopped until after the seventh week.",
"     </li>",
"     <li>",
"      Embryopathy occurred in 30 percent of the 37 pregnancies in which",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      was continued throughout the entire pregnancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Another smaller study noted embryopathy in 12 of 18 infants born to mothers who took",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/23\">",
"     23",
"    </a>",
"    ]. The most common event was a minor cosmetic defect (nasal hypoplasia); major complications were rare.",
"   </p>",
"   <p>",
"    There may be a relationship between the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    dose and fetal complications that is independent of the INR [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. This association was illustrated in a report of 71 pregnancies in 52 women with mechanical heart valves who were treated with warfarin throughout pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/11\">",
"     11",
"    </a>",
"    ]. There were 30 fetal complications, including 23 spontaneous abortions, four warfarin embryopathies, and five stillbirths. Women taking more than 5 mg of warfarin daily were at much higher risk of fetal complications than those taking a lower dose (82 versus 8 percent), regardless of INR. A similar increase in risk with warfarin doses above 5",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    (88 versus 15 percent) was noted in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The actual risk of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    embryopathy resulting in a deformed, mentally retarded infant is believed to be relatively low [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/10\">",
"     10",
"    </a>",
"    ], but warfarin-related central nervous system abnormalities probably occur at an incidence greater than first trimester embryopathy, although they are clinically less severe. In light of the possibility that the risk of warfarin embryopathy, central nervous system maldevelopment, and optic injury might increase with warfarin dose and the degree of anticoagulation, therapy should be monitored meticulously using the INR to achieve a therapeutic response at the lowest possible dose. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=see_link\">",
"     \"Therapeutic use of warfarin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The long-term physical and neurologic development after prenatal coumarin exposure during pregnancy was evaluated in a case-control study of 274 such children (7 to 15 years of age) who were compared with 231 unexposed controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/25\">",
"     25",
"    </a>",
"    ]. Only 5 percent of the children were exposed to coumarins during the sixth to ninth week of development. Data were analyzed by both single and combined effects models to look for adverse outcomes in the coumarin-exposed group. No major differences in growth or overall neurologic status were found. Exposed children were at mildly increased risk for minor neurologic dysfunction and lower IQ. There was a suggestion that the risk of adverse outcome was related to maternal coumarin dose; however, this was not statistically significant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Fetal hemorrhage",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immaturity of fetal enzyme systems and the relatively low concentration of vitamin K-dependent clotting factors render the fetus more sensitive than the mother to the anticoagulant effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/3,16,17\">",
"     3,16,17",
"    </a>",
"    ]. Thus, the transplacental passage of warfarin increases the risk of hemorrhagic fetal death during vaginal delivery. To minimize this risk, warfarin should be discontinued after 34 to 36 weeks of gestation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cesarean delivery should be considered [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Management is more complex if preterm labor develops in a patient on",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    , because both the mother and the fetus are anticoagulated. Vitamin K administration does not achieve immediate reversal of maternal anticoagulation, which may persist for 24 hours; more rapid reversal requires the transfusion of fresh frozen plasma. Importantly, fetal levels of coagulation factors do not correlate with maternal levels, and infusion of fresh frozen plasma into the mother does not reliably reverse fetal anticoagulation. A cesarean delivery may prevent hemorrhagic fetal death, and fresh frozen plasma should be administered to the neonate. Maternal subcutaneous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    generally should be resumed no later than six hours after delivery in anticipation of an early return to warfarin. Because only an inactive warfarin metabolite finds its way into breast milk, lactation does not result in neonatal anticoagulation [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H608411\">",
"    <span class=\"h3\">",
"     Postpartum use",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     Warfarin",
"    </a>",
"    can be used in the postpartum period. Nursing mothers can safely take the drug because there is no convincing evidence that warfarin exerts an anticoagulant effect on the breastfed infant [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unfractionated heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     Heparin",
"    </a>",
"    is an indirect thrombin inhibitor that complexes with antithrombin and converts this circulating cofactor from a slow to a rapid inactivator of thrombin, factor Xa, factor IXa, and to a lesser extent, factors XIIa and XIa [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (as distinguished from low-molecular-weight heparin) has a high molecular weight, which precludes transplacental transfer. Heparin is in FDA pregnancy category C (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ); it is devoid of known teratogenic risk and does not anticoagulate the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Early estimates of heparin-related fetal wastage were believed to approximate those of pregnant women receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    (ie, maternal anticoagulation was considered the major risk factor, regardless of the agent used). However, subsequent studies found a significantly lower heparin-related risk of fetal wastage that was similar to that of untreated women [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A number of concerns are related to sustained administration of unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during pregnancy, including the relative difficulty of maintaining a stable therapeutic response, the inconvenience of parenteral administration, and the complications of heparin-induced thrombocytopenia and bone demineralization in patients treated for more than seven weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/13,32-36\">",
"     13,32-36",
"    </a>",
"    ]. Demineralization can result in the fracture of vertebral bodies or long bones, and the defect may not be entirely reversible [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H2#H2\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of heparin'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link&amp;anchor=H4#H4\">",
"     \"Drugs that affect bone metabolism\", section on 'Heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Higher doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    are necessary for pregnant women to achieve therapeutic levels for both prophylaxis and therapy. The increased requirement is a result of increases in heparin-binding proteins, plasma volume, renal clearance, coagulation factors, and heparin degradation by the placenta during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/38-40\">",
"     38-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When full anticoagulation is desired, the dose can be adjusted based upon the activated partial thromboplastin time (aPTT) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    levels, as in nonpregnant individuals. However, there is no consensus regarding the optimal dose of prophylactic heparin for pregnant women. In these patients, 5000 units given subcutaneously every 12 hours probably is not sufficient to maintain a mid-interval level of 0.05 to 0.25",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/39,41\">",
"     39,41",
"    </a>",
"    ]. The appropriate dose of prophylactic heparin should be determined based on mid-interval heparin levels; if this is not possible, a dose of 7500 to 10,000 units given subcutaneously every 12 hours is a reasonable alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Women who are anticoagulated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    until the onset of labor generally experience vaginal delivery with no greater blood loss than nonanticoagulated gravidas. However, cesarean delivery in heparinized patients is accompanied by a significantly greater blood loss than would otherwise be anticipated. The heparin infusion should be stopped approximately four hours before cesarean delivery. If preterm labor develops in a patient receiving heparin, only the mother is anticoagulated, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/9/11413?source=see_link\">",
"     protamine sulfate",
"    </a>",
"    has been used to reverse maternal heparinization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     LMW heparin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low-molecular-weight",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    (LMW heparin) represents a class of anticoagulants possessing a shorter polysaccharide chain and therefore a lower molecular weight than standard, unfractionated heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. The commercially available LMW heparins are made via different processes, including nitrous acid, alkaline, or enzymatic depolymerization. These agents differ chemically and pharmacokinetically; however, the clinical significance of these differences and their potential importance in pregnancy are unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/43,46\">",
"     43,46",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     Enoxaparin",
"    </a>",
"    , the most commonly used LMW heparin in the United States, is listed by the FDA in pregnancy category B (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=see_link&amp;anchor=H29#H29\">",
"     \"Therapeutic use of heparin and low molecular weight heparin\", section on 'Use of LMW heparin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    may resolve the difficulty in achieving a sustained, stable therapeutic response and may reduce the inconvenience of parenteral administration because increased bioavailability and a longer half-life produce a more predictable anticoagulant response to fixed doses administered once or twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/44,45\">",
"     44,45",
"    </a>",
"    ]. Laboratory monitoring of the anticoagulant effect of LMW heparin is generally not performed in nonpregnant patients, but some authors recommend measuring anti-factor Xa levels four hours after injection in pregnant patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/28\">",
"     28",
"    </a>",
"    ]. The dose of LMW heparin is then titrated to achieve the manufacturer's recommended peak anti-Xa level.",
"   </p>",
"   <p>",
"    Pregnant women may need dose adjustments as the pregnancy continues because of weight gain and other factors [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/47-51\">",
"     47-51",
"    </a>",
"    ]. One study of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    pharmacokinetics in 24 women at 12, 24, and 36 weeks of gestation and 6 weeks postpartum found peak anti-X activity levels during pregnancy were lower than in nonpregnant (postpartum) women and occurred later after injection, 4 versus 2 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    causes less in vitro clot inhibition while retaining its in vivo antithrombotic effect, theoretically making the risk of bleeding less than with unfractionated heparin; it also appears less likely to precipitate heparin-associated thrombocytopenia [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is unclear whether bone loss may be significantly reduced or prevented by using LMW instead of unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    . A study that randomly assigned 44 pregnant women to receive either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/56/32648?source=see_link\">",
"     dalteparin",
"    </a>",
"    (target anti-Xa greater than 0.20",
"    <span class=\"nowrap\">",
"     IU/mL",
"    </span>",
"    three hours after injection) or unfractionated heparin (mean dose 17,250",
"    <span class=\"nowrap\">",
"     units/day)",
"    </span>",
"    found that mean bone density (BMD) in the lumbosacral spine was significantly lower one week to three years postpartum among women receiving unfractionated heparin [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/37\">",
"     37",
"    </a>",
"    ]. In addition, there was no difference in the BMD of women treated with LMW heparin compared with controls (healthy postpartum women not exposed to either heparin therapy). However, other studies have not found a difference in BMD changes between the two heparin preparations (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    versus unfractionated heparin) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/53\">",
"     53",
"    </a>",
"    ], or among patients treated with LMW heparin and matched controls [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/54\">",
"     54",
"    </a>",
"    ]. Therefore, significant uncertainty remains regarding the relationship between different heparin preparations and maternal bone loss. Accordingly, more large studies are needed to clarify whether LMW heparin is less deleterious to BMD than unfractionated heparin in pregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=see_link\">",
"     \"Drugs that affect bone metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Clinical experience with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    during pregnancy largely has been favorable [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/13,55-59\">",
"     13,55-59",
"    </a>",
"    ], and the American College of Obstetricians and Gynecologists has stated that LMW heparin can be considered in women who are candidates for prophylactic or therapeutic anticoagulation during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/60\">",
"     60",
"    </a>",
"    ]. One study, for example, evaluated the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    (20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    in 69 pregnancies in 61 women at high risk for venous thromboembolism (VTE); one woman (1.6 percent) had a postpartum pulmonary embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/56\">",
"     56",
"    </a>",
"    ]. In addition, a 1999 review found that, after adjustment for comorbid conditions, the incidence of adverse pregnancy outcomes of 486 women treated with LMW heparin was comparable to that in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/46\">",
"     46",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/18/41254?source=see_link\">",
"     Danaparoid",
"    </a>",
"    has been used in pregnant patients who require continuing anticoagulation despite the development of heparin-associated thrombocytopenia or other heparin-induced complications [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/32,61\">",
"     32,61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review of 64 studies involving 2777 pregnancies reported on the safety and efficacy of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    when used to treat or prevent VTE or for prior adverse pregnancy outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/59\">",
"     59",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      VTE and arterial thrombosis were reported in 0.86 and 0.50 percent, respectively. There were no maternal deaths.",
"     </li>",
"     <li>",
"      Significant bleeding, generally associated with obstetric causes, occurred in 1.98 percent, allergic skin reactions in 1.80 percent, and osteoporotic fractures in 0.04 percent. There were no cases of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      -induced thrombocytopenia.",
"     </li>",
"     <li>",
"      Live births were reported in 94.7 percent, including 85.4 percent in those receiving LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for recurrent pregnancy loss.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The report concluded that LMWH is both safe and effective to prevent or treat VTE in pregnancy.",
"   </p>",
"   <p>",
"    Some reports in nonpregnant patients have described a higher incidence of epidural hematoma associated with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    administration near the time of epidural catheter placement or removal [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. For this reason, patients should be switched to subcutaneous unfractionated heparin about two weeks prior to the expected delivery; this will permit regional anesthesia for labor and possible operative delivery.",
"   </p>",
"   <p>",
"    Use of LMW heparins has not been associated with a risk of birth defects above the baseline risk in the general population or with a specific type of anomaly. Prefilled, single dose syringes are preservative free. The multidose vial contains benzyl alcohol, which can have adverse fetal effects and is contraindicated in pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Mechanical prosthetic heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;Concern has been raised about the safety and efficacy of LMWH in pregnant women with mechanical prosthetic heart valves. Small observational studies and case reports have suggested that the serious complication of valve thrombosis may be more common in women treated with LMWH than with UFH or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=see_link&amp;anchor=H9#H9\">",
"     \"Complications of prosthetic heart valves\", section on 'Valve thrombosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In July 2002, the United States Food and Drug Administration issued an addition to the warnings section of product labeling for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/24/36233?source=see_link\">",
"     enoxaparin",
"    </a>",
"    , indicating that this product is",
"    <strong>",
"     not",
"    </strong>",
"    recommended for thromboprophylaxis in pregnant women with prosthetic heart valves. Similar warnings have been given by the American College of Obstetricians and Gynecologists and the European Society of Cardiology. However, other expert panels disagree, and the American College of Chest Physicians recommended that LMWH remain a therapeutic option in this setting. Detailed discussion of the management of pregnant women with prosthetic heart valves is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF SPECIFIC CONDITIONS REQUIRING ANTICOAGULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The need for anticoagulation during pregnancy is most commonly related to valvular heart disease or venous thromboembolism. The optimal management of these conditions during pregnancy remains controversial because of the absence of definitive clinical trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     General recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the approaches to anticoagulation from the 2012 ACCP Guidelines, which have given a strong recommendation for the use of LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    for both the prevention and treatment of VTE during the entire pregnancy, preferring this treatment over the use of unfractionated heparin or vitamin K antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      should be discontinued at least 24 hours prior to induction of labor or cesarean section or expected time of neuraxial anesthesia, rather than continuing this treatment up to the time of delivery.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       Heparin",
"      </a>",
"      can be restarted 12 hours post-cesarean delivery and six hours post-vaginal birth if no significant bleeding has occurred. Heparin is either continued or replaced with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      (stopping the heparin when the INR is therapeutic). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link\">",
"       \"Management of anticoagulation before and after elective surgery\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regimens that were advocated by previous versions of the ACCP Guidelines, such as adjusted dose unfractionated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    throughout the pregnancy and the use of a vitamin K antagonist during the second trimester with LMW or unfractionated heparin in the first and third trimesters, are now felt to be inferior to the approach described in the 2012 Guidelines.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H74238593\">",
"    <span class=\"h2\">",
"     Women attempting to become pregnant",
"    </span>",
"    &nbsp;&mdash;&nbsp;For women who are taking long-term vitamin K antagonists and are attempting to become pregnant, the 2012 ACCP Guidelines have made a weak suggestion in favor of performing frequent pregnancy tests and substituting treatment with LMW",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    as soon as pregnancy is achieved, rather than switching to a LMW heparin preparation while attempting pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We believe that this is a reasonable option for a woman who meets",
"    <strong>",
"     all",
"    </strong>",
"    of the following criteria:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      She has regular monthly menstrual cycles.",
"     </li>",
"     <li>",
"      She agrees to have a blood pregnancy test within the first seven days of the missed first day of expected menses. This can be facilitated by having a standing order at a laboratory or giving her laboratory requisitions in advance.",
"     </li>",
"     <li>",
"      She can be switched to a LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      preparation promptly if the pregnancy test is positive, and will have a second blood pregnancy test if the first test is negative and menses have not begun within 10 days of the missed first day of expected menses.",
"     </li>",
"     <li>",
"      She understands the baseline risk of birth defects (3 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/65\">",
"       65",
"      </a>",
"      ]) in the population and the further increased risk and types of embryopathy if she continues to take her long-term vitamin K antagonist during or after the sixth week of pregnancy (ie, &ge;14 days after the missed first day of expected menses).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Teratogenic effects'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Prosthetic heart valves",
"    </span>",
"    &nbsp;&mdash;&nbsp;In pregnant women with mechanical prosthetic valves, anticoagulants are, with few exceptions, obligatory, especially in light of the hypercoagulable state during late pregnancy. This important issue is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=see_link\">",
"     \"Management of pregnant women with prosthetic heart valves\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Venous thromboembolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of venous thromboembolism (VTE) is increased in association with pregnancy and during the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/28\">",
"     28",
"    </a>",
"    ]. This phenomenon may relate in part to the progressive increase in resistance to activated protein C that is normally observed in the second and third trimesters [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/66\">",
"     66",
"    </a>",
"    ]. Other coagulation changes that contribute to the development of VTE include: a progressive increase in several coagulation factors, such as factors I, II, VII, VIII, and X [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/67-69\">",
"     67-69",
"    </a>",
"    ]; increased activity of the fibrinolytic inhibitors PAI-1 and PAI-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/70,71\">",
"     70,71",
"    </a>",
"    ]; increased venous stasis; and vascular damage at the time of delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The risk during both the antepartum and postpartum periods appears to be accentuated in those women who have an inherited abnormality or deficiency of a naturally occurring anticoagulant, such as factor V Leiden, prothrombin G20210A, antithrombin, protein C, or protein S [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/72\">",
"     72",
"    </a>",
"    ]. In several studies, for example, the frequency of developing VTE during pregnancy or the postpartum period was at least eightfold greater in women with protein C or S deficiency, factor V Leiden, or prothrombin gene mutation G20210A than in normals [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/73,74\">",
"     73,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevention, diagnosis, and treatment of venous thromboembolism (VTE) in pregnancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=see_link\">",
"     \"Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anticoagulation may be warranted in several other conditions during pregnancy that are discussed in detail elsewhere. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Atrial fibrillation associated with significant underlying heart disease, but not lone atrial fibrillation (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=see_link\">",
"       \"Antithrombotic therapy to prevent embolization in atrial fibrillation\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Antiphospholipid antibody syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=see_link\">",
"       \"Treatment of the antiphospholipid syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Heart failure, particularly in the presence of a ventricular thrombus (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=see_link\">",
"       \"Management of heart failure in pregnancy\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"       \"Peripartum cardiomyopathy\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Eisenmenger syndrome (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H6#H6\">",
"       \"Medical management of Eisenmenger syndrome\", section on 'Pregnancy'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Paroxysmal nocturnal hemoglobinuria (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=see_link&amp;anchor=H19#H19\">",
"       \"Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria\", section on 'Prophylactic anticoagulation'",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9371507\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Strategies to maintain therapeutic anticoagulation during pregnancy while avoiding maternal or fetal harm are based largely upon retrospective data because ethical and legal considerations make large prospective trials among pregnant women difficult to conduct.",
"     </li>",
"     <li>",
"      There is convincing evidence that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      administration is potentially teratogenic and can cause fetal bleeding. Embryopathy is most likely with exposure during the sixth to ninth weeks of gestation, but toxicity after this period is still possible. Warfarin can be used in the postpartum period (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Warfarin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      A number of concerns are related to sustained administration of unfractionated",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      during pregnancy, including the relative difficulty of maintaining a stable therapeutic response, the inconvenience of parenteral administration, and the complications of heparin-induced thrombocytopenia and bone demineralization in patients treated for more than seven weeks. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Unfractionated heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low molecular weight (LMW)",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      may resolve the difficulty in achieving a sustained, stable therapeutic response with its once or twice daily dosing. Laboratory monitoring of the anticoagulant effect of LMW heparin is generally not performed, but some authors recommend measuring anti-factor Xa levels four hours after injection in pregnant patients [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18153/abstract/28\">",
"       28",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'LMW heparin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend that LMW",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      be used in preference to either unfractionated heparin or a vitamin K antagonist (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      ) when anticoagulation during pregnancy is required (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'General recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Newer oral anticoagulants including direct thrombin inhibitors and factor Xa inhibitors are",
"      <strong>",
"       contraindicated",
"      </strong>",
"      during pregnancy and breastfeeding. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=see_link\">",
"       \"Anticoagulants other than heparin and warfarin\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/1\">",
"      Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:160S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/2\">",
"      O'Reilly RA, Aggeler PM. Studies on coumarin anticoagulant drugs. Initiation of warfarin therapy without a loading dose. Circulation 1968; 38:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/3\">",
"      Howie PW. Anticoagulants in pregnancy. Clin Obstet Gynaecol 1986; 13:349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/4\">",
"      Rutherford SE, Phelan JP. Thromboembolic disease in pregnancy. Clin Perinatol 1986; 13:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/5\">",
"      Stevenson RE, Burton OM, Ferlauto GJ, Taylor HA. Hazards of oral anticoagulants during pregnancy. JAMA 1980; 243:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/6\">",
"      Chong MK, Harvey D, de Swiet M. Follow-up study of children whose mothers were treated with warfarin during pregnancy. Br J Obstet Gynaecol 1984; 91:1070.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/7\">",
"      Whitfield MF. Chondrodysplasia punctata after warfarin in early pregnancy. Case report and summary of the literature. Arch Dis Child 1980; 55:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/8\">",
"      Zakzouk MS. The congenital warfarin syndrome. J Laryngol Otol 1986; 100:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/9\">",
"      Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/10\">",
"      Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost 2006; 95:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/11\">",
"      Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol 2002; 99:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/12\">",
"      Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol 1999; 33:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/13\">",
"      Barbour LA. Current concepts of anticoagulant therapy in pregnancy. Obstet Gynecol Clin North Am 1997; 24:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/14\">",
"      Pauli RM, Lian JB, Mosher DF, Suttie JW. Association of congenital deficiency of multiple vitamin K-dependent coagulation factors and the phenotype of the warfarin embryopathy: clues to the mechanism of teratogenicity of coumarin derivatives. Am J Hum Genet 1987; 41:566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/15\">",
"      Menon RK, Gill DS, Thomas M, et al. Impaired carboxylation of osteocalcin in warfarin-treated patients. J Clin Endocrinol Metab 1987; 64:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/16\">",
"      Beeley L. Adverse effects of drugs in the first trimester of pregnancy. Clin Obstet Gynaecol 1986; 13:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/17\">",
"      Beeley L. Adverse effects of drugs in later pregnancy. Clin Obstet Gynaecol 1986; 13:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/18\">",
"      Ginsberg JS, Chan WS, Bates SM, Kaatz S. Anticoagulation of pregnant women with mechanical heart valves. Arch Intern Med 2003; 163:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/19\">",
"      Ginsberg JS, Hirsh J, Turner DC, et al. Risks to the fetus of anticoagulant therapy during pregnancy. Thromb Haemost 1989; 61:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/20\">",
"      Salazar E, Izaguirre R, Verdejo J, Mutchinick O. Failure of adjusted doses of subcutaneous heparin to prevent thromboembolic phenomena in pregnant patients with mechanical cardiac valve prostheses. J Am Coll Cardiol 1996; 27:1698.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/21\">",
"      Sbarouni E, Oakley CM. Outcome of pregnancy in women with valve prostheses. Br Heart J 1994; 71:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/22\">",
"      Iturbe-Alessio I, Fonseca MC, Mutchinik O, et al. Risks of anticoagulant therapy in pregnant women with artificial heart valves. N Engl J Med 1986; 315:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/23\">",
"      Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am J Med Genet 1993; 45:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/24\">",
"      Hall JG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/25\">",
"      Wesseling J, Van Driel D, Heymans HS, et al. Coumarins during pregnancy: long-term effects on growth and development of school-age children. Thromb Haemost 2001; 85:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/26\">",
"      Chesebro JH, Adams PC, Fuster V. Antithrombotic therapy in patients with valvular heart disease and prosthetic heart valves. J Am Coll Cardiol 1986; 8:41B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/27\">",
"      Rivera-Calimlim L. The significance of drugs in breast milk. Pharmacokinetic considerations. Clin Perinatol 1987; 14:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/28\">",
"      Bates SM, Greer IA, Pabinger I, et al. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:844S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/29\">",
"      Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: Heparin. American Heart Association. Circulation 1994; 89:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/30\">",
"      Hirsh J, Bauer KA, Donati MB, et al. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:141S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/31\">",
"      Ginsberg JS, Kowalchuk G, Hirsh J, et al. Heparin therapy during pregnancy. Risks to the fetus and mother. Arch Intern Med 1989; 149:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/32\">",
"      Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172). Thromb Haemost 1993; 70:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/33\">",
"      Brieger DB, Mak KH, Kottke-Marchant K, Topol EJ. Heparin-induced thrombocytopenia. J Am Coll Cardiol 1998; 31:1449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/34\">",
"      King DJ, Kelton JG. Heparin-associated thrombocytopenia. Ann Intern Med 1984; 100:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/35\">",
"      de Swiet M, Ward PD, Fidler J, et al. Prolonged heparin therapy in pregnancy causes bone demineralization. Br J Obstet Gynaecol 1983; 90:1129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/36\">",
"      Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am J Obstet Gynecol 1993; 168:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/37\">",
"      Pettil&auml; V, Leinonen P, Markkola A, et al. Postpartum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb Haemost 2002; 87:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/38\">",
"      Bremme K, Lind H, Blomb&auml;ck M. The effect of prophylactic heparin treatment on enhanced thrombin generation in pregnancy. Obstet Gynecol 1993; 81:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/39\">",
"      Dahlman TC, Hellgren MS, Blomb&auml;ck M. Thrombosis prophylaxis in pregnancy with use of subcutaneous heparin adjusted by monitoring heparin concentration in plasma. Am J Obstet Gynecol 1989; 161:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/40\">",
"      Chunilal SD, Young E, Johnston MA, et al. The APTT response of pregnant plasma to unfractionated heparin. Thromb Haemost 2002; 87:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/41\">",
"      Brancazio LR, Roperti KA, Stierer R, Laifer SA. Pharmacokinetics and pharmacodynamics of subcutaneous heparin during the early third trimester of pregnancy. Am J Obstet Gynecol 1995; 173:1240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/42\">",
"      Barbour LA, Smith JM, Marlar RA. Heparin levels to guide thromboembolism prophylaxis during pregnancy. Am J Obstet Gynecol 1995; 173:1869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/43\">",
"      Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997; 337:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/44\">",
"      Cosmi B, Hirsh J. Low molecular weight heparins. Curr Opin Cardiol 1994; 9:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/45\">",
"      Litin SC, Gastineau DA. Current concepts in anticoagulant therapy. Mayo Clin Proc 1995; 70:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/46\">",
"      Sanson BJ, Lensing AW, Prins MH, et al. Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost 1999; 81:668.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/47\">",
"      Hunt BJ, Doughty HA, Majumdar G, et al. Thromboprophylaxis with low molecular weight heparin (Fragmin) in high risk pregnancies. Thromb Haemost 1997; 77:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/48\">",
"      Thomson AJ, Walker ID, Greer IA. Low-molecular-weight heparin for immediate management of thromboembolic disease in pregnancy. Lancet 1998; 352:1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/49\">",
"      Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG 2003; 110:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/50\">",
"      Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004; 191:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/51\">",
"      Norris LA, Bonnar J, Smith MP, et al. Low molecular weight heparin (tinzaparin) therapy for moderate risk thromboprophylaxis during pregnancy. A pharmacokinetic study. Thromb Haemost 2004; 92:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/52\">",
"      Sephton V, Farquharson RG, Topping J, et al. A longitudinal study of maternal dose response to low molecular weight heparin in pregnancy. Obstet Gynecol 2003; 101:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/53\">",
"      Backos M, Rai R, Thomas E, et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum Reprod 1999; 14:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/54\">",
"      Carlin AJ, Farquharson RG, Quenby SM, et al. Prospective observational study of bone mineral density during pregnancy: low molecular weight heparin versus control. Hum Reprod 2004; 19:1211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/55\">",
"      Melissari E, Parker CJ, Wilson NV, et al. Use of low molecular weight heparin in pregnancy. Thromb Haemost 1992; 68:652.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/56\">",
"      Nelson-Piercy C, Letsky EA, de Swiet M. Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. Am J Obstet Gynecol 1997; 176:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/57\">",
"      Dulitzki M, Pauzner R, Langevitz P, et al. Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies. Obstet Gynecol 1996; 87:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/58\">",
"      Ellison J, Walker ID, Greer IA. Antenatal use of enoxaparin for prevention and treatment of thromboembolism in pregnancy. BJOG 2000; 107:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/59\">",
"      Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy. Blood 2005; 106:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/60\">",
"      American College of Obstetricians and Gynecologists. ACOG Committee Opinion: safety of Lovenox in pregnancy. Obstet Gynecol 2002; 100:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/61\">",
"      Lindhoff-Last E, Kreutzenbeck HJ, Magnani HN. Treatment of 51 pregnancies with danaparoid because of heparin intolerance. Thromb Haemost 2005; 93:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/62\">",
"      Lumpkin MM. FDA public health advisory. Anesthesiology 1998; 88:27A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/63\">",
"      Wysowski DK, Talarico L, Bacsanyi J, Botstein P. Spinal and epidural hematoma and low-molecular-weight heparin. N Engl J Med 1998; 338:1774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/64\">",
"      Bates SM, Greer IA, Middeldorp S, et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e691S.",
"     </a>",
"    </li>",
"    <li>",
"     CDC. Update on Overall Prevalence of Major Birth Defects --- Atlanta, Georgia, 1978--2005 file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5701a2.htm (Accessed on May 24, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/66\">",
"      Walker MC, Garner PR, Keely EJ, et al. Changes in activated protein C resistance during normal pregnancy. Am J Obstet Gynecol 1997; 177:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/67\">",
"      Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335:108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/68\">",
"      McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost 1997; 78:1183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/69\">",
"      Hellgren M, Blomb&auml;ck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest 1981; 12:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/70\">",
"      Kruithof EK, Tran-Thang C, Gudinchet A, et al. Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood 1987; 69:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/71\">",
"      Gerbasi FR, Bottoms S, Farag A, Mammen E. Increased intravascular coagulation associated with pregnancy. Obstet Gynecol 1990; 75:385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/72\">",
"      Haemostasis and Thrombosis Task Force, British Committee for Standards in Haematology. Investigation and management of heritable thrombophilia. Br J Haematol 2001; 114:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/73\">",
"      Friederich PW, Sanson BJ, Simioni P, et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis. Ann Intern Med 1996; 125:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18153/abstract/74\">",
"      Gerhardt A, Scharf RE, Beckmann MW, et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342:374.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1342 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18153=[""].join("\n");
var outline_f17_46_18153=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H9371507\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H883650\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COMMON ANTITHROMBOTIC AGENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Warfarin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Teratogenic effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Fetal hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H608411\">",
"      - Postpartum use",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unfractionated heparin",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      LMW heparin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Mechanical prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT OF SPECIFIC CONDITIONS REQUIRING ANTICOAGULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      General recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H74238593\">",
"      Women attempting to become pregnant",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Venous thromboembolism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9371507\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/1342\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1342|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?23/62/24558\" title=\"figure 1\">",
"      Coagulation pathways",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/1342|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/59/37818?source=related_link\">",
"      Anticoagulants other than heparin and warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/32/42506?source=related_link\">",
"      Antithrombotic therapy to prevent embolization in atrial fibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/57/25497?source=related_link\">",
"      Complications of prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/27/39353?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Epidemiology, pathogenesis, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/46/14055?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3351?source=related_link\">",
"      Deep vein thrombosis and pulmonary embolism in pregnancy: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/43/17082?source=related_link\">",
"      Diagnosis and treatment of paroxysmal nocturnal hemoglobinuria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/21/9562?source=related_link\">",
"      Drugs that affect bone metabolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/34/1577?source=related_link\">",
"      Management of heart failure in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/53/1882?source=related_link\">",
"      Management of pregnant women with prosthetic heart valves",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/8/33930?source=related_link\">",
"      Therapeutic use of heparin and low molecular weight heparin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/17/42266?source=related_link\">",
"      Therapeutic use of warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/12/23754?source=related_link\">",
"      Treatment of the antiphospholipid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/56/23432?source=related_link\">",
"      Vitamin K and the synthesis of gamma carboxyglutamic acid",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18154="Treatment of intermittent and mild persistent asthma in adolescents and adults";
var content_f17_46_18154=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of intermittent and mild persistent asthma in adolescents and adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Christopher H Fanta, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Bruce S Bochner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?17/46/18154/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?17/46/18154/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 8, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A basic tenet of asthma therapy is that the intensity of treatment should match the severity of asthmatic symptoms. As a result, patients with infrequent and mild symptoms of asthma should be treated intermittently with the goal of quick symptom relief. Patients with mild symptoms that are persistent or present regularly should additionally receive a long-term controller medication. As with all types of asthma, effective communication, ongoing patient education, and regular reassessment of asthma control are crucial for long term success.",
"   </p>",
"   <p>",
"    The issues relating to the treatment of intermittent and persistent mild asthma in adults and adolescents will be discussed here, with an emphasis on pharmacologic therapy. The recommendations made in this review are based upon the National Asthma Education and Prevention Program (NAEPP) guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ], as well as similar guidelines published by the Global Initiative for Asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. An overview of the management of asthma, and reviews of the treatment of other severities of asthma, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=see_link\">",
"     \"Treatment of severe asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild asthma may be classified as intermittent or as mild persistent. Classification of asthma in general is based upon an assessment of current impairment of function and future risk of exacerbations with the latter based on the number of serious exacerbations within the past year [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Reported daytime and nighttime symptoms and exercise limitation over the previous two to four weeks",
"     </li>",
"     <li>",
"      Current values of peak expiratory flow (PEF) or forced expiratory volume in 1 second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) and forced expiratory volume in 1",
"      <span class=\"nowrap\">",
"       second/forced",
"      </span>",
"      vital capacity",
"      <span class=\"nowrap\">",
"       (FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC)",
"      </span>",
"      (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=see_link\">",
"       \"Peak expiratory flow rate monitoring in asthma\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=see_link\">",
"       \"Office spirometry\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Number of exacerbations requiring oral glucocorticoids in the previous year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The use of these three categories of asthma morbidity to determine asthma severity is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Intermittent asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intermittent asthma is characterized by the following (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daytime asthma symptoms occurring two or fewer days per week",
"     </li>",
"     <li>",
"      Two or fewer nocturnal awakenings per month",
"     </li>",
"     <li>",
"      Use of short-acting beta agonists to relieve symptoms fewer than two days a week",
"     </li>",
"     <li>",
"      No interference with normal activities between exacerbations",
"     </li>",
"     <li>",
"      PEF or FEV",
"      <sub>",
"       1",
"      </sub>",
"      measurements when asymptomatic that are consistently within the normal range (ie, &gt;80 percent of predicted normal)",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio is normal (based upon age-adjusted values) when asymptomatic",
"     </li>",
"     <li>",
"      One or no exacerbations requiring oral glucocorticoids per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the patient has impairment that is greater than that described in any one of these categories, the severity of asthma should be categorized as more severe than intermittent asthma. However, a person using an inhaled bronchodilator preventively prior to exercise to avoid exercise-induced bronchoconstriction may also have intermittent asthma, even if exercising more than two days per week. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Others, in whom asthmatic symptoms arise only under certain infrequently occurring circumstances (eg, upon encountering a cat or during a viral respiratory tract infection) are also considered to have intermittent asthma, even if the exacerbations are significant, provided that oral glucocorticoids are not required more than once per year (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mild persistent asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild persistent asthma is characterized by PEF or FEV",
"    <sub>",
"     1",
"    </sub>",
"    measurements within normal range (&ge;80 percent of predicted normal), a normal",
"    <span class=\"nowrap\">",
"     FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio, and the presence of any one of the following (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Symptoms more than two days a week (although less than daily)",
"     </li>",
"     <li>",
"      Three to four nocturnal awakenings per month due to asthma",
"     </li>",
"     <li>",
"      Use of short-acting beta agonists to relieve symptoms more than two times a week (but not daily)",
"     </li>",
"     <li>",
"      Minor interference with normal activities",
"     </li>",
"     <li>",
"      Two or more exacerbations requiring oral glucocorticoids per year",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Inclusion of the criterion &ldquo;two or more glucocorticoid-requiring exacerbations in the past year&rdquo; is based on the observations that such patients have an increased risk of future exacerbations and that regular use of anti-inflammatory therapy reduces this risk. Thus, asthma experts advise regular use of antiinflammatory therapy for these patients, even in the absence of frequent asthma symptoms, nighttime awakenings, or impairment of normal activity level.",
"   </p>",
"   <p>",
"    A patient with symptoms suggestive of mild persistent asthma and the spirometric pattern",
"    <span class=\"nowrap\">",
"     (FEV",
"     <sub>",
"      1",
"     </sub>",
"     /FVC",
"    </span>",
"    ratio below normal, but FEV",
"    <sub>",
"     1",
"    </sub>",
"    &ge;80 percent predicted) would be characterized as having mild persistent asthma, especially if bronchodilator responsiveness is documented.",
"   </p>",
"   <p>",
"    These criteria for mild persistent asthma are appropriately applied to persons who are, at the time of assessment, taking no regular medications for control of their asthma. They are not applicable to persons with asthma already using regular controller medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Moderate persistent asthma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of any of the following is considered an indication of moderate asthma severity (",
"    <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Daily symptoms of asthma",
"     </li>",
"     <li>",
"      Nocturnal awakenings more than once per week",
"     </li>",
"     <li>",
"      Daily need for short-acting beta agonists for symptom relief",
"     </li>",
"     <li>",
"      More than just minor limitation in normal activity",
"     </li>",
"     <li>",
"      FEV",
"      <sub>",
"       1",
"      </sub>",
"      between 60 and 80 percent of predicted and an",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      ratio less than the lower confidence interval for normal; age-dependent normal ranges for",
"      <span class=\"nowrap\">",
"       FEV",
"       <sub>",
"        1",
"       </sub>",
"       /FVC",
"      </span>",
"      are provided in the table (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 1",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with moderate persistent asthma require pharmacologic therapy beyond that recommended for mild asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=see_link\">",
"     \"Treatment of moderate persistent asthma in adolescents and adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NON-PHARMACOLOGIC THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Non-pharmacologic therapies for intermittent and mild persistent asthma are essential components of management and include trigger avoidance and patient education.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Trigger avoidance",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elimination or avoidance of known triggers is a useful strategy to help control the disease. History taking is crucial in determining exposure to environmental allergens and irritants in the home, school,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    workplace. This topic is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"     \"Trigger control to enhance asthma management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"     \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Patient education",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patient education is an ongoing process that is intended to create a partnership between the patient and provider in achieving and maintaining asthma control. In addition to educational materials, every patient with asthma should be provided with a personalized asthma action plan that gives detailed instructions about how to self-administer medications at baseline and during exacerbations (",
"    <a class=\"graphic graphic_form graphicRef55900 \" href=\"UTD.htm?36/39/37498\">",
"     form 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=see_link\">",
"     \"What do patients need to know about their asthma?\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     IMPACT OF PHARMACOTHERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary goals of treatment are relief of patient symptoms, prevention of acute asthmatic attacks, and improved quality of life. Evidence is lacking to support the concept that therapy alters the natural history of asthma (ie, the risk of progressive loss of lung function over time, as occurs in a subset of asthmatic patients).",
"   </p>",
"   <p>",
"    Asthma is associated with a chronic eosinophilic bronchitis that can progress over time to cause permanent structural changes in the airway wall associated with irreversible airflow obstruction. However, in some patients, the airway inflammation can persist into old age without permanent change in lung function. The development of irreversible airways obstruction appears to occur most often in those with longstanding, severe disease or a history of severe asthma exacerbations [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=see_link\">",
"     \"Natural history of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It would clearly be preferable to identify those patients who are destined to progress to permanent pulmonary impairment and intervene early to prevent progression to irreversible airflow obstruction. Unfortunately, the ability to predict the progression of mild asthma in this way is lacking at present. No epidemiologic studies have been performed that provide long-term physiologic (lung function) and histologic follow-up of a large cohort of adults with mild asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One clinical trial in adults found that delayed initiation of antiinflammatory therapy (ie, inhaled glucocorticoids) appeared to be less beneficial than treatment begun closer to the initial diagnosis of asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. This observation suggested that inhaled glucocorticoids might help prevent the changes in lung function that occur in some patients over time. However, several subsequent studies found that inhaled glucocorticoids did not prevent disease progression or abnormalities in lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/8-11\">",
"     8-11",
"    </a>",
"    ]. Thus, there is currently no evidence that antiinflammatory therapy protects against irreversible airway obstruction over time.",
"   </p>",
"   <p>",
"    As a result, many experts feel that the cost and inconvenience of regular controller therapy, combined with the benign natural history of intermittent or mild persistent asthma in most patients, argue against universal antiinflammatory treatment in an attempt to achieve long-term preservation of lung function [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/12\">",
"     12",
"    </a>",
"    ]. Thus, the primary goals of treatment remain focused on relief of patient symptoms and prevention of acute asthmatic attacks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     MEDICATIONS FOR INTERMITTENT ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with infrequent and mild symptoms of asthma are best treated with intermittent use of an inhaled, short-acting, beta-2-selective adrenergic agonist (SABA), corresponding to Step 1 therapy (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1,13\">",
"     1,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Inhaled beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The currently available inhaled SABAs have a rapid onset of action (within five minutes), an intermediate duration of effect (approximately four to six hours), and relative beta-2 selectivity (",
"    <a class=\"graphic graphic_table graphicRef62770 \" href=\"UTD.htm?42/7/43132\">",
"     table 2",
"    </a>",
"    ). The inhaled route of administration is preferred over oral administration because of the shorter time to relief, greater potency of bronchodilation, and fewer side effects [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Patients who develop asthmatic symptoms as a result of predictable triggers (eg, exercise-induced bronchoconstriction) are encouraged to use their SABA approximately 10 to 20 minutes prior to exposure in order to prevent the development of symptoms. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link\">",
"     \"Exercise-induced bronchoconstriction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    SABAs alone are not sufficient for an individual patient if symptoms are not fully relieved, or if symptoms recur consistently, such that SABAs are needed more than two days a week on a regular basis (excluding special circumstances, such as during a viral respiratory infection). Such patients should be treated for mild persistent asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Delivery mechanisms",
"    </span>",
"    &nbsp;&mdash;&nbsp;SABAs are available in metered-dose inhalers (MDIs) and in solutions for nebulization. Worldwide, there has been a transition away from MDIs using chlorofluorocarbon (CFC) propellants to those using the environmentally-safe propellant hydrofluoroalkane (HFA). The differences between CFC and HFA-based inhalers are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link&amp;anchor=H85082029#H85082029\">",
"     \"The use of inhaler devices in adults\", section on 'Metered dose inhalers with CFC and HFA'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=see_link&amp;anchor=H3#H3\">",
"     \"The use of inhaler devices in children\", section on 'Propellants'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HFA formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    include ProAir-HFA, Proventil-HFA, and Ventolin-HFA. An albuterol MDI with an HFA propellant has the same onset of action, duration of effect, and side effect profile as albuterol with CFC propellant, even though patients often experience a difference. The perceived difference probably relates to the fact that the plume of medication released from albuterol-HFA devices has a slower speed and less chilled temperature compared with the medication plume from traditional albuterol-CFC inhalers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HFA inhalers have a propensity to clog at the point where the nozzle of the metal canister is seated in the well of its plastic holder. To prevent this problem, it is recommended that once weekly patients remove the canister from its plastic holder, rinse water through the holder, allow it to air-dry, and then reinsert the metal canister. In addition, the MDI should be primed before use and again if the canister has not been used for two or more weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some alternative delivery mechanisms are presently available and still others are likely to be introduced in the near future. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      is available in a dry powder form in some countries, although no longer in the United States. Inhalational technique may be easier for some patients with the dry powder form because the devices are breath-actuated, so that patients do not need to coordinate inhalation with release of the dose.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/57/20372?source=see_link\">",
"       Pirbuterol",
"      </a>",
"      is available in a breath-actuated delivery device called an Autohaler. The pressurized canister is actuated by inspiratory airflow at the mouthpiece, thereby ensuring medication delivery at the start of inspiration.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"       Levalbuterol",
"      </a>",
"      is the dextro-rotatory isomer of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      , purified from the racemic mixture of s- and d-isomers that comprises albuterol. It is available as a liquid for nebulization and as an MDI (Xopenex-HFA). Each puff contains 45 mcg of levalbuterol (compared with 90 mcg of albuterol). Its onset and duration of action are comparable to albuterol.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Some patients experience tremulousness, palpitations,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anxiety from the systemic effects of inhaled SABAs. Using a single inhalation of drug for prevention or relief of symptoms rather than the usual two puffs may alleviate these adverse reactions with a minimal decrease in bronchodilator effect. It had been hoped that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/27/43445?source=see_link\">",
"     levalbuterol",
"    </a>",
"    might cause fewer stimulatory side effects than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"     albuterol",
"    </a>",
"    , but this difference has not been demonstrated with certainty. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=see_link&amp;anchor=H5#H5\">",
"     \"Beta agonists in asthma: Acute administration and prophylactic use\", section on 'Levalbuterol'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Other agents",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"     Ipratropium",
"    </a>",
"    and oral beta agonists are generally less effective than inhaled beta agonists for symptom relief in intermittent asthma.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/37/33360?source=see_link\">",
"       Ipratropium",
"      </a>",
"      &ndash; Ipratropium (Atrovent) is an anticholinergic agent that has a slower onset of action (15 to 20 minutes) and achieves significantly less bronchodilation in asthma than inhaled SABAs. Its use is not recommended except in very special circumstances (eg, tachyarrhythmias due to inhaled beta agonists or concomitant use of monoamine oxidase inhibitors). A systematic review concluded that, except in the setting of acute, severe asthmatic attacks, combination therapy with ipratropium and SABAs is not superior to SABAs alone in adults with asthma [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Oral beta agonists &ndash; Oral beta agonists (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       albuterol",
"      </a>",
"      in liquid or tablet formulation) generally do not make good alternative bronchodilators for mild asthma. They take longer to begin to work, achieve less bronchodilation, and are associated with more side effects than when the same medication is delivered by inhalation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Cromoglycates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cromolyn (Intal) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    are alternative medications for prevention of exercise-induced bronchoconstriction or prevention of asthma symptoms caused by predictable allergic exposures (eg, visiting a home with a cat) (",
"    <a class=\"graphic graphic_table graphicRef56418 \" href=\"UTD.htm?32/17/33052\">",
"     table 3",
"    </a>",
"    ). Neither cromolyn nor nedocromil is currently available in the United States in a metered dose inhaler; the only remaining formulation for asthma is the solution of cromolyn for nebulization. HFA-based and dry powder inhaler formulations for cromolyn and nedocromil are available in many other countries.",
"   </p>",
"   <p>",
"    These agents prevent bronchospasm through mast-cell stabilizing and other properties, although they DO NOT have acute bronchodilating capacity. They have the advantage of being virtually devoid of adverse side effects, aside from a mildly unpleasant taste with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    that is experienced by some individuals. No other short- or long-term adverse consequences have been identified. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link\">",
"     \"The use of chromones (cromoglycates) in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two inhalations of either cromolyn or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/43/691?source=see_link\">",
"     nedocromil",
"    </a>",
"    , taken approximately 10 to 20 minutes prior to exercise or other trigger exposure have been shown to be effective preventive treatment in blinded, placebo-controlled studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. These medications provide additive protection when used in combination with an inhaled beta agonist prior to exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prescription of inhaled beta agonists as monotherapy for intermittent asthma has the advantage of providing both prevention and relief of symptoms, compared to the cromoglycates, which are preventive only.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     MEDICATIONS FOR MILD PERSISTENT ASTHMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is appropriate to begin regular treatment with antiinflammatory medications when a patient has one or more of the characteristics of mild persistent asthma. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Mild persistent asthma'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The preferred long-term controller agents for mild persistent asthma are low-dose inhaled glucocorticoids. Alternative agents are leukotriene modifying drugs, mast cell stabilizing agents (cromoglycates), and sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    , although the latter two therapies are increasingly obsolete. The NAEPP guidelines do not express a preference for any one of these three alternative agents over another, although clinical practice favors the leukotriene receptor antagonists [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients receiving long-term controller medications for mild persistent asthma should continue to use their SABAs as needed for relief of symptoms and prior to exposure to known triggers of their symptoms. Regular use (four times daily) of SABAs provides no advantage over as needed use and may have harmful effects in some patients [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. There is also no advantage to inhaling a bronchodilator immediately prior to use of an inhaled glucocorticoid. In patients with mild asthma, medication distribution and deposition within the lungs are adequate without bronchodilator pretreatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids (commonly called inhaled steroids) are now considered the agents of choice in all patients with persistent asthma according to the 2007 guidelines from the National Asthma Education and Prevention Program (NAEPP) (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link\">",
"     \"An overview of asthma management\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regular treatment with inhaled glucocorticoids reduces the frequency of symptoms (and the need for inhaled bronchodilators), improves the overall quality of life, and decreases the risk of serious exacerbations for patients with asthma [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/22-28\">",
"     22-28",
"    </a>",
"    ]. In addition, by reducing airway inflammation, this therapy may alter the basic property of the airways that makes them asthmatic, reducing their exaggerated sensitivity to any and all triggers of asthma (bronchial hyperresponsiveness) [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/22\">",
"     22",
"    </a>",
"    ]. Representative studies demonstrating the efficacy of inhaled glucocorticoids include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/22-29\">",
"     22-29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multicenter, double-blind trial randomly assigned over 7000 patients with mild persistent asthma to treatment with low-dose inhaled",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (400 mcg once daily) or placebo for three years [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/23\">",
"       23",
"      </a>",
"      ]. Early initiation of budesonide was associated with decreased risk of a severe asthma exacerbation during the study period (hazard ratio 0.56; 95% CI 0.45-0.71). Patients who were treated with budesonide demonstrated better pulmonary function and experienced fewer days with symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/23,30\">",
"       23,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second controlled trial randomized 103 patients with recent onset mild asthma to either high-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      (600 mcg twice daily) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      (375 mcg twice daily) [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/24\">",
"       24",
"      </a>",
"      ]. At one and two year follow-up, budesonide therapy was associated with a greater increase in morning PEFR (32.8 versus 4.8",
"      <span class=\"nowrap\">",
"       L/min",
"      </span>",
"      with terbutaline), fewer asthma symptoms, and decreased need for supplemental beta-2 agonists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Two studies have examined whether patients with mild persistent asthma need daily controller therapy or might be managed instead with a plan that called for initiation of controller therapy (inhaled or oral glucocorticoids) only during periods of increased asthma symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/31-33\">",
"     31-33",
"    </a>",
"    ]. The largest was a randomized trial that examined the outcomes of 225 patients with mild persistent asthma treated with as-needed inhaled or oral glucocorticoids (for exacerbations) while taking one of three daily therapies: inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    , oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    (a leukotriene receptor antagonist), or placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/31\">",
"     31",
"    </a>",
"    ]. After one year, there were more symptom-free days in the group taking daily inhaled budesonide, but there were no differences between the groups in the rate of severe exacerbations, impairment in quality of life, or loss of pulmonary function. These results raise the possibility that future recommendations for treating mild asthma may call for daily controller medications only if patients have a greater burden of asthmatic symptoms than in the current guidelines. The optimal threshold at which patients should begin to take daily controller medication has yet to be defined by experimental observations.",
"   </p>",
"   <p>",
"    Not all patients with asthma are responsive to inhaled glucocorticoid therapy. Studies suggest that up to 35 percent of patients may not experience improvements in FEV",
"    <sub>",
"     1",
"    </sub>",
"    or bronchial hyperresponsiveness [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=see_link\">",
"     \"Glucocorticoid-resistant asthma\"",
"    </a>",
"    .) In some studies, patients with mild asthma who continue to smoke appear relatively resistant to the effects of low-dose inhaled glucocorticoids, although this has not been confirmed in all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/36-39\">",
"     36-39",
"    </a>",
"    ]. The optimal choice of medications for treating asthma in patients who continue to smoke has not been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Initial dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial dose of inhaled glucocorticoids for mild persistent asthma should be in the low-dose range, corresponding to Step 2 treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. The usual starting dose and the different types of inhaled glucocorticoids are shown in the low dose column in the table (",
"    <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Only one agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/15/36080?source=see_link\">",
"     mometasone",
"    </a>",
"    , has been approved for once-daily dosing. The other inhaled glucocorticoids have traditionally been administered twice daily, although it is likely that they can be used once daily in patients with mild asthma, which might improve compliance [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/40,41\">",
"     40,41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    More evidence supports the safety of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    during pregnancy than for the other inhaled glucocorticoids. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=see_link\">",
"     \"Management of asthma during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Delivery devices and spacers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inhaled glucocorticoids are available via MDI, dry powder inhaler (DPI), and as a solution for nebulization. Use of a valved holding chamber (\"spacer\") device with MDI glucocorticoids is recommended in order to maximize medication delivery to the bronchi and to minimize oropharyngeal deposition. Available spacers include Aerochamber, Optichamber, Ellipse, Vortex, and others. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=see_link\">",
"     \"The use of inhaler devices in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Spacers are not used with DPIs. DPIs and MDIs each have different advantages and drawbacks. These are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=see_link\">",
"     \"Delivery of inhaled medication in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The local and systemic side effects of inhaled glucocorticoids, as well as strategies for minimizing them, are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=see_link\">",
"     \"Major side effects of inhaled glucocorticoids\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis\", section on 'Effect of inhaled glucocorticoids'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Long-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"     formoterol",
"    </a>",
"    are inhaled long-acting beta agonists (LABAs) with a duration of action of at least 12 hours. These medications, although classified as long-term controllers, should only be used in combination with a concomitant antiinflammatory agent, preferably an inhaled glucocorticoid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"     \"Beta agonists in asthma: Controversy regarding chronic use\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Monotherapy with LABAs is inferior to monotherapy with inhaled glucocorticoids. In the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"     Salmeterol",
"    </a>",
"    or Inhaled Corticosteroids trial of the Asthma Clinical Research Network, patients whose asthma was well-controlled on moderate doses of inhaled glucocorticoids were randomly assigned to continue the inhaled glucocorticoid or to switch to twice-daily salmeterol [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/42\">",
"     42",
"    </a>",
"    ]. Although the two groups achieved similar peak flow values, the frequency of treatment failures (primarily exacerbations requiring an intensification of treatment) was significantly greater in the group receiving salmeterol alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Inhaled glucocorticoids plus long-acting beta agonists",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of inhaled glucocorticoids plus long-acting beta agonists (LABAs) is NOT currently recommended by the NAEPP guidelines as a therapeutic option for mild persistent asthma, for the following reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Monotherapy with inhaled glucocorticoids is effective and usually sufficient to control mild persistent asthma.",
"     </li>",
"     <li>",
"      Concern has been raised about the potential for LABAs (ie,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      ) to cause an increased risk of fatal and near-fatal asthmatic attacks [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/43\">",
"       43",
"      </a>",
"      ]. As a result, the United States FDA has issued a public health advisory strongly warning against the use of LABAs (alone or in combination with an inhaled glucocorticoid) as treatment for mild asthma. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=see_link\">",
"       \"Beta agonists in asthma: Controversy regarding chronic use\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Future directions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intriguing, but unapproved, alternative strategies for mild persistent asthma include once daily or as-needed use of combination inhalers containing either a LABA or a short-acting beta agonist (SABA) plus an inhaled glucocorticoid. These approaches have not been included in the recommendations of the 2007 NAEPP guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/44\">",
"     44",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy containing inhaled glucocorticoid plus a LABA, administered once daily, may be as effective as twice daily administration of an inhaled glucocorticoid alone [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/45\">",
"       45",
"      </a>",
"      ]. In a randomized trial of 500 patients with mild persistent asthma, once daily administration of combined",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/63/34806?source=see_link\">",
"       salmeterol",
"      </a>",
"      and low-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"       fluticasone",
"      </a>",
"      (100 mcg daily) proved equally as effective as twice daily inhaled fluticasone (200 mcg daily) and superior to the leukotriene receptor antagonist,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       montelukast",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/45\">",
"       45",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Once daily plus as-needed dosing has also been examined using the combination of the LABA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?13/52/14151?source=see_link\">",
"       formoterol",
"      </a>",
"      , with the inhaled glucocorticoid (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"       budesonide",
"      </a>",
"      160",
"      <span class=\"nowrap\">",
"       mcg/day).",
"      </span>",
"      In a randomized trial of 697 patients with mild to moderate asthma, once daily and as-needed use of this combination was compared to once-daily use of twice the dose of budesonide (320",
"      <span class=\"nowrap\">",
"       mcg/day)",
"      </span>",
"      plus as-needed use of the SABA,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"       terbutaline",
"      </a>",
"      . The morning peak expiratory flow rate and exacerbation rate were better in the combination inhaler group [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/46\">",
"       46",
"      </a>",
"      ]. One advantage of using the combined form of formoterol and inhaled glucocorticoid is that patients can use a single inhaler for both routine maintenance therapy and for quick relief of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Although not available in the United States, combination SABA and inhaled glucocorticoid devices have been utilized elsewhere for control of mild persistent asthma. Patients can obtain quick-relief from the SABA and simultaneously receive an anti-inflammatory inhaled glucocorticoid. The more often they have symptoms requiring quick relief, the more anti-inflammatory therapy they receive [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/48\">",
"       48",
"      </a>",
"      ]. However, it is uncertain whether the dose of inhaled glucocorticoids administered in these circumstances is optimal.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Leukotriene modifying drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The sulfidopeptide leukotrienes (leukotriene C4, D4, and E4) are potent chemical mediators of the allergic response in asthma. Their actions include stimulation of bronchoconstriction (1000-fold more potent than histamine), mucus hypersecretion, microvascular leakage with edema formation, and eosinophil chemoattraction. Two types of medications that block these leukotriene effects are now available: a 5-lipoxygenase enzyme inhibitor that blocks production of leukotrienes, and leukotriene receptor antagonists that competitively inhibit the action of leukotrienes at their receptor. The differences between these medications are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Availability and dosing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The leukotriene modifying drugs in use in the United States include",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/33/17940?source=see_link\">",
"     zileuton",
"    </a>",
"    &nbsp;(",
"    <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"     table 5",
"    </a>",
"    ). All are orally administered. Zileuton currently requires monitoring for liver function abnormalities and is not recommended for routine use in mild persistent asthma (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"       Zafirlukast",
"      </a>",
"      (Accolate) was the first drug available in the category of leukotriene receptor antagonists (LTRAs). In adolescents and adults, the dosing for zafirlukast is 20 mg administered twice daily. Absorption is optimized by ingestion of the medication on an empty stomach. Zafirlukast is metabolized in the liver by CYP2C9. The only significant drug interaction is with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , resulting in an increase in the prothrombin time.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"       Montelukast",
"      </a>",
"      (Singulair) is also a LTRA. The dose in adolescents and adults is 10 mg once daily [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/49\">",
"       49",
"      </a>",
"      ]. No significant drug interactions have been reported. In most clinical trials montelukast was administered in the evening; however, there is no clinical evidence that favors evening versus morning dosing.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26634393\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The post-marketing experience with both LTRAs revealed an association with eosinophilic vasculitis (Churg-Strauss syndrome). This association was reported in a small number of patients, many of whom had had their oral glucocorticoids withdrawn in concert with initiation of LTRAs. A causal association between LTRAs and Churg-Strauss syndrome has not been established, and many experts believe that the more likely explanation is that glucocorticoid withdrawal simply unmasks the preexisting disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=see_link&amp;anchor=H7#H7\">",
"     \"Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)\", section on 'Leukotriene modifying agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Reports have emerged describing the rare onset of depression and suicidal ideation among patients taking LTRAs. An FDA review of the topic indicated that depression and behavioral changes can be linked to treatment with LTRAs, but that suicide does not occur with increased frequency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical trials in patients with mild to moderate asthma have demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/49/37654?source=see_link\">",
"     montelukast",
"    </a>",
"    induce persistent bronchodilation and improve symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/50-52\">",
"     50-52",
"    </a>",
"    ]. In addition, these drugs decrease the need for rescue use of short-acting beta agonist inhalers and, in some studies, protect against acute asthmatic exacerbations requiring oral glucocorticoids. In general, medication adherence is high with oral medications administered only once or twice-daily [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The leukotriene modifying drugs, however, are generally less effective than inhaled glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/35,54,55\">",
"     35,54,55",
"    </a>",
"    ]. As an example, one randomized trial of 451 patients found that those treated with low-dose inhaled",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/45/39632?source=see_link\">",
"     fluticasone",
"    </a>",
"    had significantly greater improvements in lung function and number of symptom-free days and less use of rescue medications than patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/54/20325?source=see_link\">",
"     zafirlukast",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/54\">",
"     54",
"    </a>",
"    ]. On the other hand, when the greater efficacy of inhaled glucocorticoids is balanced against the greater compliance with oral medication, the two types of medications appear to achieve similar outcomes in &ldquo;real world&rdquo; practice [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It appears that some people with asthma respond well to the leukotriene-blocking drugs, whereas others do not. These differences likely relate to variability among patients in the relative contribution of leukotriene over-expression to the pathogenesis of their asthma. Tests to identify patients who are &ldquo;over-expressers&rdquo; of leukotrienes are not clinically available, although asthmatic persons with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     aspirin",
"    </a>",
"    sensitivity (ie, asthma made acutely worse by ingestion of aspirin or nonsteroidal antiinflammatory drugs) typically make excess amounts of leukotrienes. Leukotriene modifying agents are generally effective in these patients. The role of antileukotriene therapy in aspirin exacerbated respiratory disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=see_link&amp;anchor=H21#H21\">",
"     \"Aspirin exacerbated respiratory disease\", section on 'Leukotriene modifying agents'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-leukotriene agents may also be helpful in two additional settings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with both mild persistent asthma and allergic rhinitis, use of an LTRA may allow reduction in the number of medications needed to control allergic rhinitis. Leukotriene receptor antagonists are effective in the treatment of seasonal and perennial allergic rhinitis, with a potency comparable to second-generation antihistamines. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=see_link&amp;anchor=H25107466#H25107466\">",
"       \"Pharmacotherapy of allergic rhinitis\", section on 'Montelukast'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      When exercise-induced bronchospasm is a prominent feature, an LTRA can be used to prevent exercise-induced symptoms. Chronic use of LTRAs is not associated with tachyphylaxis, unlike long-acting inhaled beta agonists [",
"      <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/57\">",
"       57",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=see_link&amp;anchor=H14#H14\">",
"       \"Exercise-induced bronchoconstriction\", section on 'Antileukotriene agents'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Responders and non-responders to the anti-leukotriene agents can be best distinguished on the basis of a therapeutic trial. Failure to improve after approximately a month of therapy constitutes a negative response. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=see_link\">",
"     \"Agents affecting the 5-lipoxygenase pathway in the treatment of asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Theophylline",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    is an alternative long-acting bronchodilator and in the past was used as a controller medication for persistent asthma. It is not preferred because its antiinflammatory properties are at best modest, side effects are common, and blood levels must be monitored in order to avoid toxicity. However, it may be an attractive therapeutic option in an occasional patient due to its low cost, oral administration in tablet form, and established safety during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Sustained-release",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/31/30200?source=see_link\">",
"     theophylline",
"    </a>",
"    is given to achieve a serum concentration between 5 and 15",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Periodic theophylline monitoring is necessary to maintain a therapeutic level and avoid toxicity. The risk of serious, potentially life-threatening toxicity, plus availability of alternative long-acting bronchodilators, have led to the dramatic decline in use of theophylline over the last three decades. The dosing and proper administration of theophylline in asthma is presented in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=see_link\">",
"     \"Theophylline use in asthma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     LONG-TERM MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient's level of asthma control should be assessed at each medical visit. The 2007 NAEPP guidelines replaced regular assessments of severity with assessments of control [",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. Assessments of control should be based upon the interim clinical history (for which validated questionnaires such as the Asthma Control Test and Asthma Control Questionnaire are available), current pulmonary function, and the patient's level of risk of future asthma exacerbations. In brief, the criteria for good asthma control are the same criteria, listed above, used to establish asthma severity as intermittent. The concept of asthma control is presented in more detail separately and is summarized in the figure (",
"    <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"     table 6",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=see_link&amp;anchor=H27#H27\">",
"     \"An overview of asthma management\", section on 'Assessing control to adjust therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h2\">",
"     Stepping up therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the patient's asthma is not well-controlled by initial therapy, then medication technique and adherence, along with trigger avoidance, should be reviewed in detail. If no problems are identified in these areas, the patient's therapy should be \"stepped up\" to the next level (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. The patient should be reevaluated in two to six weeks following a change in therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h2\">",
"     Stepping down therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stepping down therapy when possible is an important means of reducing the overall drug exposure over the course of a lifetime. Some patients have asthma that is best categorized as intermittent during some times of the year, and persistent during others. Such patients may alternate between step 1 and step 2 therapy (",
"    <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?17/46/18154/abstract/1\">",
"     1",
"    </a>",
"    ]. In mild asthma, this may mean using inhaled glucocorticoids regularly during periods of increased asthmatic symptoms and discontinuing them when symptoms (and SABA use) are infrequent. This strategy requires considerable patient education and explanation, so that patients will understand the difference between the &ldquo;as-needed&rdquo; use of short-acting beta agonists for acute relief of symptoms (&ldquo;rescue&rdquo;) compared with the &ldquo;intermittent&rdquo; use of inhaled glucocorticoids taken every day for a few weeks or months during periods of increased asthma symptoms (&ldquo;controller therapy&rdquo;).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basic topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=see_link\">",
"       \"Patient information: Medicines for asthma (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=see_link\">",
"       \"Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=see_link\">",
"       \"Patient information: Trigger avoidance in asthma (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=see_link\">",
"       \"Patient information: How to use a peak flow meter (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=see_link\">",
"       \"Patient information: Asthma inhaler techniques in adults (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Clinical overview",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with infrequent and mild symptoms of asthma should be treated intermittently with the goal of quick symptom relief. Patients with mild symptoms that are persistent or present regularly should additionally receive long-term controller therapy, which, in the case of inhaled glucocorticoids, should be initiated at a low dose. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Both intermittent and mild persistent asthma are characterized by a peak expiratory flow (PEF) or forced expiratory volume in one second (FEV",
"      <sub>",
"       1",
"      </sub>",
"      ) greater than 80 percent of predicted between exacerbations. Intermittent asthma and mild persistent asthma differ in the frequency of daily and nocturnal symptoms and the number of exacerbations requiring oral glucocorticoids per year (",
"      <a class=\"graphic graphic_table graphicRef58247 \" href=\"UTD.htm?32/48/33549\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification of Asthma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The natural history of asthma has not been adequately studied, and it is currently not possible to predict the course of chronic mild asthma in individual patients. A small minority of patients with mild asthma may worsen and develop irreversible airways obstruction over time, although most will not. The factors predisposing to this outcome are unknown, and antiinflammatory therapies have not been definitively shown to be protective. As a result, the primary goals of treatment are relief of symptoms and prevention of acute attacks, rather than the long-term preservation of lung function. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Impact of Pharmacotherapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Treatment recommendations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An essential part of asthma management is identification and avoidance of known triggers (with the exception of exercise). History taking is crucial in determining exposure to environmental allergens and irritants in the home",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      workplace. Allergy skin testing or immunoassays for specific immunoglobulin E in the blood can then supplement the history by identifying sensitivity to common aeroallergens. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=see_link\">",
"       \"Trigger control to enhance asthma management\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=see_link\">",
"       \"Allergen avoidance in the treatment of asthma and allergic rhinitis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For optimal control of asthma symptoms, we recommend basing pharmacologic therapy upon current national and international guidelines (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h3\">",
"     Intermittent",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with intermittent symptoms of asthma, we recommend a short-acting inhaled beta-2-selective adrenergic agonist (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). This represents step 1 therapy (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/61/16344?source=see_link\">",
"       Albuterol",
"      </a>",
"      in a metered-dose inhaler (MDI) device is commonly used, although other SABA preparations are available (",
"      <a class=\"graphic graphic_table graphicRef62770 \" href=\"UTD.htm?42/7/43132\">",
"       table 2",
"      </a>",
"      ). We recommend use as-needed for relief of acute symptoms as well as for prevention of symptoms caused by exercise or trigger exposure, as opposed to regularly-scheduled administration (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Inhaled beta agonists'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cromoglycates can be used as alternative preventative agents (eg, prior to exercise), although they have no acute bronchodilatory properties and a beta-2-selective adrenergic agonist must still be prescribed for acute bronchodilation (",
"      <a class=\"graphic graphic_table graphicRef56418 \" href=\"UTD.htm?32/17/33052\">",
"       table 3",
"      </a>",
"      ). Their utility has been diminished by withdrawal of MDI formulations from the market in most countries. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cromoglycates'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=see_link\">",
"       \"The use of chromones (cromoglycates) in the treatment of asthma\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h3\">",
"     Mild persistent",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with mild persistent asthma, we suggest daily antiinflammatory medication (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). This represents step 2 (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ). In addition, a short-acting inhaled beta agonist should be administered as-needed (",
"      <a class=\"graphic graphic_table graphicRef62770 \" href=\"UTD.htm?42/7/43132\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      We recommend inhaled glucocorticoids as initial long-term controller therapy, in keeping with current national and international guidelines (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). Initial dosing should be in the low-dose range for the specific agent (",
"      <a class=\"graphic graphic_table graphicRef78011 \" href=\"UTD.htm?15/35/15934\">",
"       table 4",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Inhaled glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative approach is use of an oral leukotriene receptor antagonist (",
"      <a class=\"graphic graphic_table graphicRef77367 \" href=\"UTD.htm?20/12/20683\">",
"       table 5",
"      </a>",
"      ). Patients failing to improve with leukotriene modifying therapy should be switched to an inhaled glucocorticoid. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Leukotriene modifying drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Increasing evidence suggests that at least some patients with mild persistent asthma can use their anti-inflammatory therapy intermittently (that is, taken daily during periods of increased symptoms, then discontinued 1 to 2 weeks after symptoms have abated). This approach has yet to be recommended in guidelines developed by national and international panels. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Future directions'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H34\">",
"       'Stepping down therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h3\">",
"     Chronic therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The patient's asthma control should be reassessed at each visit for asthma care (",
"      <a class=\"graphic graphic_table graphicRef53233 \" href=\"UTD.htm?38/33/39453\">",
"       table 6",
"      </a>",
"      ). Return visits should also allow for ongoing",
"      <span class=\"nowrap\">",
"       patient/family",
"      </span>",
"      education. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Long-term management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Therapy should be stepped up if asthma is not well-controlled, and stepped down if symptoms have been well-controlled over a period of months (",
"      <a class=\"graphic graphic_figure graphicRef56729 \" href=\"UTD.htm?43/33/44563\">",
"       figure 1",
"      </a>",
"      ). Patients should be reevaluated every 2 to 6 weeks when therapy has been adjusted. (See",
"      <a class=\"local\" href=\"#H32\">",
"       'Long-term management'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma. Bethesda, MD: National Heart, Lung, and Blood Institute, 2007. (NIH publication no. 08-4051) www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     file://www.ginasthma.org/Guidelines/guidelines-resources.html (Accessed on January 05, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/3\">",
"      Limb SL, Brown KC, Wood RA, et al. Irreversible lung function deficits in young adults with a history of childhood asthma. J Allergy Clin Immunol 2005; 116:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/4\">",
"      Burrows B, Bloom JW, Traver GA, Cline MG. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N Engl J Med 1987; 317:1309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/5\">",
"      Rijcken B, Weiss ST. Longitudinal analyses of airway responsiveness and pulmonary function decline. Am J Respir Crit Care Med 1996; 154:S246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/6\">",
"      Haahtela T, J&auml;rvinen M, Kava T, et al. Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 1994; 331:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/7\">",
"      Haahtela T, Tamminen K, Kava T, et al. Thirteen-year follow-up of early intervention with an inhaled corticosteroid in patients with asthma. J Allergy Clin Immunol 2009; 124:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/8\">",
"      Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 2000; 343:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/9\">",
"      Bisgaard H, Hermansen MN, Loland L, et al. Intermittent inhaled corticosteroids in infants with episodic wheezing. N Engl J Med 2006; 354:1998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/10\">",
"      Murray CS, Woodcock A, Langley SJ, et al. Secondary prevention of asthma by the use of Inhaled Fluticasone propionate in Wheezy INfants (IFWIN): double-blind, randomised, controlled study. Lancet 2006; 368:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/11\">",
"      Guilbert TW, Morgan WJ, Zeiger RS, et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N Engl J Med 2006; 354:1985.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/12\">",
"      Israel E, Drazen JM. Treating mild asthma--when are inhaled steroids indicated? N Engl J Med 1994; 331:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/13\">",
"      Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med 1995; 333:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/14\">",
"      Shim C, Williams MH Jr. Bronchial response to oral versus aerosol metaproterenol in asthma. Ann Intern Med 1980; 93:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/15\">",
"      Shim C, Williams MH Jr. Comparison of oral aminophylline and aerosol metaproterenol in asthma. Am J Med 1981; 71:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/16\">",
"      Westby M, Benson M, Gibson P. Anticholinergic agents for chronic asthma in adults. Cochrane Database Syst Rev 2004; :CD003269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/17\">",
"      Woolley M, Anderson SD, Quigley BM. Duration of protective effect of terbutaline sulfate and cromolyn sodium alone and in combination on exercise-induced asthma. Chest 1990; 97:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/18\">",
"      Bundgaard A, Enehjelm SD, Schmidt A. A comparative study of the effects of two different doses of nedocromil sodium and placebo given by pressurised aerosol in exercise-induced bronchoconstriction. Allergy 1988; 43:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/19\">",
"      Latimer KM, O'Byrne PM, Morris MM, et al. Bronchoconstriction stimulated by airway cooling. Better protection with combined inhalation of terbutaline sulphate and cromolyn sodium than with either alone. Am Rev Respir Dis 1983; 128:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/20\">",
"      Drazen JM, Israel E, Boushey HA, et al. Comparison of regularly scheduled with as-needed use of albuterol in mild asthma. Asthma Clinical Research Network. N Engl J Med 1996; 335:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/21\">",
"      Dennis SM, Sharp SJ, Vickers MR, et al. Regular inhaled salbutamol and asthma control: the TRUST randomised trial. Therapy Working Group of the National Asthma Task Force and the MRC General Practice Research Framework. Lancet 2000; 355:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/22\">",
"      Juniper EF, Kline PA, Vanzieleghem MA, et al. Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. Am Rev Respir Dis 1990; 142:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/23\">",
"      Pauwels RA, Pedersen S, Busse WW, et al. Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 2003; 361:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/24\">",
"      Haahtela T, J&auml;rvinen M, Kava T, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/25\">",
"      Dutoit JI, Salome CM, Woolcock AJ. Inhaled corticosteroids reduce the severity of bronchial hyperresponsiveness in asthma but oral theophylline does not. Am Rev Respir Dis 1987; 136:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/26\">",
"      Donahue JG, Weiss ST, Livingston JM, et al. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/27\">",
"      Adams NP, Bestall JC, Lasserson TJ, et al. Fluticasone versus placebo for chronic asthma in adults and children. Cochrane Database Syst Rev 2005; :CD003135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/28\">",
"      Adams N, Bestall J, Jones PW. Budesonide for chronic asthma in children and adults. Cochrane Database Syst Rev 2001; :CD003274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/29\">",
"      Busse WW, Pedersen S, Pauwels RA, et al. The Inhaled Steroid Treatment As Regular Therapy in Early Asthma (START) study 5-year follow-up: effectiveness of early intervention with budesonide in mild persistent asthma. J Allergy Clin Immunol 2008; 121:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/30\">",
"      O'Byrne PM, Pedersen S, Busse WW, et al. Effects of early intervention with inhaled budesonide on lung function in newly diagnosed asthma. Chest 2006; 129:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/31\">",
"      Boushey HA, Sorkness CA, King TS, et al. Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 2005; 352:1519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/32\">",
"      Turpeinen M, Nikander K, Pelkonen AS, et al. Daily versus as-needed inhaled corticosteroid for mild persistent asthma (The Helsinki early intervention childhood asthma study). Arch Dis Child 2008; 93:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/33\">",
"      Chauhan BF, Chartrand C, Ducharme FM. Intermittent versus daily inhaled corticosteroids for persistent asthma in children and adults. Cochrane Database Syst Rev 2013; 2:CD009611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/34\">",
"      Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol 2002; 109:410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/35\">",
"      Malmstrom K, Rodriguez-Gomez G, Guerra J, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/36\">",
"      Tomlinson JE, McMahon AD, Chaudhuri R, et al. Efficacy of low and high dose inhaled corticosteroid in smokers versus non-smokers with mild asthma. Thorax 2005; 60:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/37\">",
"      Lazarus SC, Chinchilli VM, Rollings NJ, et al. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 2007; 175:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/38\">",
"      Thomson NC. Smokers with asthma: what are the management options? Am J Respir Crit Care Med 2007; 175:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/39\">",
"      O'Byrne PM, Lamm CJ, Busse WW, et al. The effects of inhaled budesonide on lung function in smokers and nonsmokers with mild persistent asthma. Chest 2009; 136:1514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/40\">",
"      Selroos O, Edsb&auml;cker S, Hultquist C. Once-daily inhaled budesonide for the treatment of asthma: clinical evidence and pharmacokinetic explanation. J Asthma 2004; 41:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/41\">",
"      Masoli M, Weatherall M, Holt S, Beasley R. Budesonide once versus twice-daily administration: meta-analysis. Respirology 2004; 9:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/42\">",
"      Holgate ST. Therapeutic options for persistent asthma. JAMA 2001; 285:2637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/43\">",
"      Lalloo UG, Malolepszy J, Kozma D, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma. Chest 2003; 123:1480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/44\">",
"      Kraft M, Israel E, O'Connor GT. Clinical Decisions. Treatment of mild persistent asthma. N Engl J Med 2007; 356:2096.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/45\">",
"      American Lung Association Asthma Clinical Research Centers, Peters SP, Anthonisen N, et al. Randomized comparison of strategies for reducing treatment in mild persistent asthma. N Engl J Med 2007; 356:2027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/46\">",
"      Rabe KF, Pizzichini E, St&auml;llberg B, et al. Budesonide/formoterol in a single inhaler for maintenance and relief in mild-to-moderate asthma: a randomized, double-blind trial. Chest 2006; 129:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/47\">",
"      Oppenheimer JJ, Peters SP. Is the maintenance and reliever approach the answer? Ann Allergy Asthma Immunol 2010; 104:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/48\">",
"      Papi A, Canonica GW, Maestrelli P, et al. Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 2007; 356:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/49\">",
"      Jarvis B, Markham A. Montelukast: a review of its therapeutic potential in persistent asthma. Drugs 2000; 59:891.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/50\">",
"      Suissa S, Dennis R, Ernst P, et al. Effectiveness of the leukotriene receptor antagonist zafirlukast for mild-to-moderate asthma. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1997; 126:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/51\">",
"      Israel E, Cohn J, Dub&eacute; L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 1996; 275:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/52\">",
"      Kraft M, Cairns CB, Ellison MC, et al. Improvements in distal lung function correlate with asthma symptoms after treatment with oral montelukast. Chest 2006; 130:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/53\">",
"      Rand C, Bilderback A, Schiller K, et al. Adherence with montelukast or fluticasone in a long-term clinical trial: results from the mild asthma montelukast versus inhaled corticosteroid trial. J Allergy Clin Immunol 2007; 119:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/54\">",
"      Bleecker ER, Welch MJ, Weinstein SF, et al. Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma. J Allergy Clin Immunol 2000; 105:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/55\">",
"      Nathan RA, Bleecker ER, Kalberg C, Fluticasone Propionate Study Group. A comparison of short-term treatment with inhaled fluticasone propionate and zafirlukast for patients with persistent asthma. Am J Med 2001; 111:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/56\">",
"      Price D, Musgrave SD, Shepstone L, et al. Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 2011; 364:1695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/57\">",
"      Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?17/46/18154/abstract/58\">",
"      Yurdakul AS, Taci N, Eren A, Sipit T. Comparative efficacy of once-daily therapy with inhaled corticosteroid, leukotriene antagonist or sustained-release theophylline in patients with mild persistent asthma. Respir Med 2003; 97:1313.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 527 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18154=[""].join("\n");
var outline_f17_46_18154=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H36\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION OF ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Intermittent asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mild persistent asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Moderate persistent asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NON-PHARMACOLOGIC THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Trigger avoidance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Patient education",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      IMPACT OF PHARMACOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      MEDICATIONS FOR INTERMITTENT ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Inhaled beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Delivery mechanisms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Other agents",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Cromoglycates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      MEDICATIONS FOR MILD PERSISTENT ASTHMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Initial dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Delivery devices and spacers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Long-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Inhaled glucocorticoids plus long-acting beta agonists",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Future directions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Leukotriene modifying drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Availability and dosing",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26634393\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Theophylline",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      LONG-TERM MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      Stepping up therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Stepping down therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Clinical overview",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      - Intermittent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      - Mild persistent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      - Chronic therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/527\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/527|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?43/33/44563\" title=\"figure 1\">",
"      Stepwise asthma Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/527|Form\">",
"      <a href=\"#\" title=\"FORMS\">",
"       FORMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_form\" href=\"UTD.htm?36/39/37498\" title=\"form 1\">",
"      Asthma action plan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/527|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/48/33549\" title=\"table 1\">",
"      Initiating Rx 12 and up",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/7/43132\" title=\"table 2\">",
"      Short acting beta agonists adult",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/17/33052\" title=\"table 3\">",
"      Dosing of cromolyn sodium and nedocromil in asthma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/35/15934\" title=\"table 4\">",
"      Inhaled GC doses for adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/12/20683\" title=\"table 5\">",
"      Usual doses antileukotriene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?38/33/39453\" title=\"table 6\">",
"      Adjusting Rx 12 and up",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/1/30746?source=related_link\">",
"      Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/48/34569?source=related_link\">",
"      Allergen avoidance in the treatment of asthma and allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/37/8794?source=related_link\">",
"      An overview of asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/0/39944?source=related_link\">",
"      Aspirin exacerbated respiratory disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/26/8618?source=related_link\">",
"      Beta agonists in asthma: Acute administration and prophylactic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/19/16698?source=related_link\">",
"      Beta agonists in asthma: Controversy regarding chronic use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/20/18762?source=related_link\">",
"      Delivery of inhaled medication in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/56/21383?source=related_link\">",
"      Epidemiology, pathogenesis, and pathology of Churg-Strauss syndrome (allergic granulomatosis and angiitis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/30/1513?source=related_link\">",
"      Exercise-induced bronchoconstriction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/42/7849?source=related_link\">",
"      Glucocorticoid-resistant asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/60/7114?source=related_link\">",
"      Major side effects of inhaled glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/34/29226?source=related_link\">",
"      Management of asthma during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/13/7383?source=related_link\">",
"      Natural history of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/30/5607?source=related_link\">",
"      Office spirometry",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/54/42855?source=related_link\">",
"      Pathogenesis, clinical features, and evaluation of glucocorticoid-induced osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?28/25/29075?source=related_link\">",
"      Patient information: Asthma inhaler techniques in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/63/39925?source=related_link\">",
"      Patient information: Asthma treatment in adolescents and adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?31/6/31841?source=related_link\">",
"      Patient information: How to use a peak flow meter (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?29/22/30052?source=related_link\">",
"      Patient information: Medicines for asthma (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/25/31124?source=related_link\">",
"      Patient information: Trigger avoidance in asthma (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/53/854?source=related_link\">",
"      Peak expiratory flow rate monitoring in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/60/37834?source=related_link\">",
"      Pharmacotherapy of allergic rhinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/29/471?source=related_link\">",
"      The use of chromones (cromoglycates) in the treatment of asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/26/18856?source=related_link\">",
"      The use of inhaler devices in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/57/36760?source=related_link\">",
"      The use of inhaler devices in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/57/11161?source=related_link\">",
"      Theophylline use in asthma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26745?source=related_link\">",
"      Treatment of moderate persistent asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3354?source=related_link\">",
"      Treatment of severe asthma in adolescents and adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/9/44184?source=related_link\">",
"      Trigger control to enhance asthma management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/15/31991?source=related_link\">",
"      What do patients need to know about their asthma?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f17_46_18155="Pseudo-Hutchinson sign causes";
var content_f17_46_18155=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85614&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Conditions associated with pseudo-Hutchinson sign",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Benign",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Racial melanonychia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lauzier-Hunziker syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Peutz-Jeghers syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Radiation therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Malnutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Minocycline-induced dyschromia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        AIDS",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Congenital nevus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Chronic trauma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Subungual hematoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Illusory - pigmentation within the nail bed and/or matrix seen through the transparency of the cuticle",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Malignant nonmelanoma",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bowen disease",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Source: Andr&eacute; J, Lateur N. Pigmented nail disorders. Dermatol Clin 2006; 24:329.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18155=[""].join("\n");
var outline_f17_46_18155=null;
var title_f17_46_18156="Vascular v pseudo claudicat";
var content_f17_46_18156=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F80547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F80547&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Findings that distinguish neurogenic pseudoclaudication (primarily attributable to spinal stenosis) from vascular claudication*",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       &nbsp;",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Vascular claudication,",
"       </p>",
"       <p>",
"        n = 26",
"       </p>",
"      </td>",
"      <td class=\"subtitle1\">",
"       <p>",
"        Neurogenic \"pseudoclaudication\",",
"       </p>",
"       <p>",
"        n = 23",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain on standing alone (without ambulation)",
"      </td>",
"      <td>",
"       27 percent",
"      </td>",
"      <td>",
"       65 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Pain with coughing or sneezing",
"      </td>",
"      <td>",
"       0 percent",
"      </td>",
"      <td>",
"       38 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Distance to claudication constant",
"      </td>",
"      <td>",
"       88 percent",
"      </td>",
"      <td>",
"       38 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paresthesias on walking",
"      </td>",
"      <td>",
"       12 percent",
"      </td>",
"      <td>",
"       43 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Mean time to relief of walking-induced symptoms",
"      </td>",
"      <td>",
"       5.0 minutes",
"      </td>",
"      <td>",
"       12.7 minutes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Normal femoral, popliteal, and dorsalis pedis pulses",
"      </td>",
"      <td>",
"       0 percent",
"      </td>",
"      <td>",
"       83 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Femoral or aortic bruit",
"      </td>",
"      <td>",
"       54 percent",
"      </td>",
"      <td>",
"       9 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sensory deficit",
"      </td>",
"      <td>",
"       <p>",
"        12 percent",
"       </p>",
"       <p>",
"        (always stocking distribution)",
"       </p>",
"      </td>",
"      <td>",
"       <p>",
"        55 percent",
"       </p>",
"       <p>",
"        (usually dermatomal distribution)",
"       </p>",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Limited straight leg raising",
"      </td>",
"      <td>",
"       0 percent",
"      </td>",
"      <td>",
"       30 percent",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Muscle weakness",
"      </td>",
"      <td>",
"       12 percent",
"      </td>",
"      <td>",
"       39 percent",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Values are a percentage of patients with each finding (sensitivities).",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Hawkes, CH, Roberts, GM. Neurogenic and vascular claudication. J Neurol Sci 1978; 38:337.",
"     <br>",
"      Table reproduced with permission from: McDonough, KA, Wipf, JE, Deyo, RA. Low back pain. In: Office Practice of Medicine, 4th ed, Branch, WT (Ed), Saunders 2003. Copyright &copy;2003 Elsevier Science, Inc.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18156=[""].join("\n");
var outline_f17_46_18156=null;
var title_f17_46_18157="Suggested supplies and equipment for the MH treatment cart";
var content_f17_46_18157=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67323&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Suggested supplies and equipment for the MH treatment cart",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Drugs",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dantrolene 20 mg vials",
"       </td>",
"       <td>",
"        36 vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sterile water for injection (not bacteriostatic) one liter bags, for reconstitution of dantrolene*",
"       </td>",
"       <td>",
"        2 bags",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Sodium bicarbonate 8.4%, 50 mL",
"       </td>",
"       <td>",
"        5 prefilled syringes or vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dextrose 50%, 50 mL",
"       </td>",
"       <td>",
"        2 vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Furosemide 10 mg/mL, 10 mL",
"       </td>",
"       <td>",
"        2 vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Calcium chloride 10%, 10 mL",
"       </td>",
"       <td>",
"        2 vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine 2%, 5 mL",
"       </td>",
"       <td>",
"        4 prefilled syringes or vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Amiodarone 50 mg/mL, 3 mL",
"       </td>",
"       <td>",
"        2 vials",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Refrigerated drugs and solutions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Insulin regular 100 units/mL, 10 mL",
"       </td>",
"       <td>",
"        1 vial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0.9% normal saline, 1000 mL for IV cooling",
"       </td>",
"       <td>",
"        4 bags and sterile pour bottles",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cold packs",
"       </td>",
"       <td>",
"        8 (freezer)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        General equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes, 60 mL to dilute dantrolene",
"       </td>",
"       <td>",
"        5 syringes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mini-Spike&reg; or similar IV additive pins and transfer set to reconstitute dantrolene",
"       </td>",
"       <td>",
"        2 each",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        IV catheters (IV access and arterial line): 16G, 18G, 20G 2-inch, 22G 1-inch, 24G &frac34;-inch",
"       </td>",
"       <td>",
"        4 each",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        NG tubes",
"       </td>",
"       <td>",
"        Sizes appropriate for patient population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60 cc irrigation syringe (eg, Toomey&reg;)",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Drip IV set, chamber, extension",
"       </td>",
"       <td>",
"        4 each",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Syringes (insulin, ABG, 60 mL, 10 mL, 3 mL)",
"       </td>",
"       <td>",
"        4 to 6 each",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        18G needles",
"       </td>",
"       <td>",
"        6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Monitoring equipment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Esophageal or tympanic temperature probes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Rectal or bladder and skin temperature probes",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        CVP monitoring kits",
"       </td>",
"       <td>",
"        Sizes appropriate for patient population",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transducer kits for arterial and central venous cannulation",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"2\">",
"        Nursing supplies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Large sterile plastic drape (eg, Steri-Drape&reg;)",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Urine meter",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Irrigation tray",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Small and large clear plastic bags for ice",
"       </td>",
"       <td>",
"        4 each",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Bucket for ice",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Test strips: urine analysis for hemoglobin and finger stick glucose",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     MH: malignant hyperthermia; NG: nasogastric; IV: intravenous; G: gauge; CVP: central venous pressure; ABG: arterial blood gas; %: percent.",
"     <br>",
"      * Use precaution, such as distinctive auxiliary label, to avoid accidental IV administration of hypotonic solution.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Drugs, equipment and dantrolene-managing MH. Malignant Hyperthermia Association of US. Version 1/27/2010. Available at file://medical.mhaus.org/index.cfm/fuseaction/OnlineBrochures.Display/BrochurePK/B5DBDF12-20C3-4537-948C098DAB0777E3.cfm.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18157=[""].join("\n");
var outline_f17_46_18157=null;
var title_f17_46_18158="TNF ILP unresect extrem sarcoma";
var content_f17_46_18158=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76912&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Results of TNF-based isolated limb perfusion for unresectable extremity soft tissue sarcoma",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"8\" width=\"12%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Author;",
"        <br/>",
"        year",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        n",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Treatment",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Response rate,",
"        <br/>",
"        percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Limb salvage,",
"        <br/>",
"        percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Overall survival,",
"        <br/>",
"        percent",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Local recurrence,",
"        <br/>",
"        percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Complete",
"       </td>",
"       <td class=\"subtitle2\">",
"        Partial",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Multicenter studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eggermont A; 1996",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        TNF+IFN+M",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        64 (two-year)",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eggermont A; 1996",
"       </td>",
"       <td>",
"        186",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        57",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Eggermont A; 1999",
"       </td>",
"       <td>",
"        246",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        28*",
"       </td>",
"       <td>",
"        47",
"       </td>",
"       <td>",
"        71",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"8\">",
"        Single center studies",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Gutman M; 1997",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        37",
"       </td>",
"       <td>",
"        54",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        18",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olieman A; 1998",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        35",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        LeJeune F; 2000",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        64",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        45",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Noorda E; 2003",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        58",
"       </td>",
"       <td>",
"        48",
"        <sup>",
"         &bull;",
"        </sup>",
"        (five-year)",
"       </td>",
"       <td>",
"        13",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grunhagen D; 2005",
"       </td>",
"       <td>",
"        64",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        42",
"       </td>",
"       <td>",
"        45",
"       </td>",
"       <td>",
"        82",
"       </td>",
"       <td>",
"        39 (five-year)",
"       </td>",
"       <td>",
"        45 (two-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lans T; 2005",
"       </td>",
"       <td>",
"        29",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        65",
"       </td>",
"       <td>",
"        50 (five-year)",
"       </td>",
"       <td>",
"        31 (two-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bonvalot S; 2005",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        49",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        17",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        82 (two-year)",
"       </td>",
"       <td>",
"        24 (two-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Grunhagen D; 2006",
"       </td>",
"       <td>",
"        217",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        51",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        49 (five-year)",
"       </td>",
"       <td>",
"        26",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hayes A; 2007",
"       </td>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        NR",
"       </td>",
"       <td>",
"        71",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pennacchioli E; 2007",
"       </td>",
"       <td>",
"        88",
"       </td>",
"       <td>",
"        Dox+M&plusmn;TNF",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        28",
"       </td>",
"       <td>",
"        52",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        47 (five-year)",
"       </td>",
"       <td>",
"        27 (five-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Van Ginkel R; 2007",
"       </td>",
"       <td>",
"        73",
"       </td>",
"       <td>",
"        TNF&plusmn;IFN+M",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        69",
"       </td>",
"       <td>",
"        61",
"       </td>",
"       <td>",
"        59 (five-year)",
"       </td>",
"       <td>",
"        10 (five-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bonvalot S; 2009",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        30",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        49",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        89 (three-year)",
"       </td>",
"       <td>",
"        18 (three-year)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        DiFilippo F; 2009",
"       </td>",
"       <td>",
"        75",
"       </td>",
"       <td>",
"        TNF+Dox",
"       </td>",
"       <td>",
"        34",
"       </td>",
"       <td>",
"        48",
"       </td>",
"       <td>",
"        84",
"       </td>",
"       <td>",
"        62 (five-year)",
"       </td>",
"       <td>",
"        21",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deroose J; 2011",
"       </td>",
"       <td>",
"        208",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        18",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        <p>",
"         42 (five-year)",
"        </p>",
"        33 (ten-year)",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Deroose J; 2012",
"       </td>",
"       <td>",
"        29",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        33",
"       </td>",
"       <td>",
"        38",
"       </td>",
"       <td>",
"        87",
"       </td>",
"       <td>",
"        72 (three-year)",
"       </td>",
"       <td>",
"        32",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Olofsson R; 2012",
"       </td>",
"       <td>",
"        54**",
"       </td>",
"       <td>",
"        TNF+M",
"       </td>",
"       <td>",
"        21",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        76",
"       </td>",
"       <td>",
"        44 (five-year)",
"       </td>",
"       <td>",
"        37",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     TNF: tumor necrosis factor; IFN: interferon; M: melphalan; Dox: doxorubicin; NR: not reported.",
"     <br/>",
"     * Complete response based on a complete necrosis histologically.",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Disease-specific survival.",
"     <br/>",
"     &Delta; Multiple tumors in extremity.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Previously irradiated field.",
"     <br/>",
"     &sect; Lower dose TNF.",
"     <br/>",
"     &yen; Complete response determined radiographically.",
"     <br/>",
"     &Dagger; 51 treated with TNF, 37 with non-TNF ILP.",
"     <br/>",
"     &dagger; All patients with soft tissue sarcoma in the distal parts of the limb.",
"     <br/>",
"     ** All candidates for amputation.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18158=[""].join("\n");
var outline_f17_46_18158=null;
var title_f17_46_18159="Diffuse anterior scleritis";
var content_f17_46_18159=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F55397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F55397&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diffuse anterior scleritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 330px; height: 213px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Diffuse anterior scleritis in a patient with systemic lupus erythematosus. The anterior sclera reveals diffuse redness and vascular engorgement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of M Reza Dana, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f17_46_18159=[""].join("\n");
var outline_f17_46_18159=null;
